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ABSTRACT 
 
Introduction: Acute Myeloid Leukaemia (AML) is known to be a heterogeneous 
clonal disorder of haemopoietic progenitor cells. Recently, the molecular 
pathogenesis of AML has become more apparent, with the description of two 
commonly found mutations, namely NPM1 (Nucleophosmin protein-1) gene 
mutation and the FLT3-ITD (FMS-like tyrosine kinase 3 internal tandem 
duplication) mutation. These mutations are now routinely assessed and used in 
both prognostication and treatment decisions in the first world. 
The primary aim of this project was to assess for the presence of NPM1 and FLT3-
ITD mutations in patients diagnosed with de novo AML at Charlotte Maxeke 
Johannesburg Academic Hospital. In order to achieve this aim certain objectives 
were completed. This included the establishment of a detection method for both 
NPM1 and FLT3-ITD mutations by means of PCR as well as determining the 
overall number of these mutations in the study population and assessing the 
frequency of these mutations alone and in combination. Correlation with previous 
immunophenotypic analysis, cytogenetics and other routine parameters was also 
assessed. Materials and Methods: A total of 164 cases of de novo AML were 
collected retrospectively over time period September 2004 to December 2009. A 
robust method for the detection of both NPM1 and FLT3-ITD mutations was 
established using genomic (g) DNA, extracted from blood or bone marrow aspirate 
samples. Two single PCR reactions were performed, with final analysis by means 
of capillary electrophoresis using the ABI 3130 Genetic Analyser.   
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Results: Of the 164 cases analysed, NPM1 mutations were found in 26%, while 
FLT3-ITD was present in 21% of these cases. FLT3-ITD showed preferential 
targeting of the NPM1 mutation positive cases with 44% of these cases also found 
to be NPM1 mutation positive (P<0.04). Routine parameter assessment revealed 
some novel findings. The median age at diagnosis for the NPM1 mutation positive 
only cases was 30 years; this is younger than expected. The median WCC of the 
FLT3-ITD only cases was 101x109/l which was significantly increased compared to 
the NPM1 mutation only cases (P<0.03) and those with neither mutation present 
(P<0.01). Immunophenotypic analysis revealed a statistically significant increase 
in CD14, CD11b and HLA-DR (human leucocyte antigen DR) in NPM1-mut 
positive samples. When assessing CD34 expression and NPM1-mut. NPM1-wt 
cases were significantly more likely to be CD34 positive than NPM1-mut cases. 
Recurrent genetic translocations were found to co-occur with NPM1 mutations. 
This, in particular is a rare finding which requires further investigation. 
Conclusion: This much needed test has proven to be robust in its detection of 
these gene mutations. It will certainly prove clinically relevant, especially as the 
use of molecularly targeted therapy becomes part of routine treatment. 
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1 INTRODUCTION 
1.1 INTRODUCTION TO ACUTE MYELOID LEUKAEMIA (AML) 
Adult acute myeloid leukaemia (AML) is known to be a very heterogeneous clonal 
disorder of haemopoietic progenitor cells with expansion of myeloid blasts in the 
peripheral blood, bone marrow and other tissues (Estey and Döhner, 2006). 
This is a result of the inability of the cells to regulate proliferation, together with 
inhibition of differentiation (Kelly and Gilliland, 2002). 
The incidence of AML in North America is approximately 3.5 cases per 100 000 
population per year with a median age at diagnosis of 67 years and a slight male 
predominance  (Swerdlow et al., 2008, Jemal et al., 2009). There is currently very 
little published data with regards to the epidemiology and diagnosis of AML in 
South Africa and it was therefore set out, as part of the aims of this study, to better 
elucidate this. 
The first classification of AML was proposed by Galton and Dacie in 1976 (Galton, 
1975) and this was followed shortly thereafter by the French American British 
(FAB) classification, which is still used today, in conjunction with other 
classifications (Bennett et al., 1976). These earlier classifications were based 
solely on morphology and cyto-chemical staining results. Subsequently, the World 
Health Organization (WHO) Classification of Tumours of Haemopoietic and 
Lymphoid Tissues and in particular the 3rd edition (2001) was introduced which, 
although largely based on the FAB classification, includes both cytogenetic and 
immunophenotypic analysis as key components in making the diagnosis and 
assessing the prognosis of AML (Jaffe et al., 2001).  
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More recently the importance of newly identified gene abnormalities in the 
pathogenesis of AML has come to light. The 4th edition (2008) of the WHO 
classification now includes the new category of AML with gene mutations and 
within that, two new provisional entities: AML with mutated Nucleophosmin 
Member 1 Protein (NPM1) and AML with mutated CCAAT Enhancer Binding 
Protein α (CEBPA) (Swerdlow et al., 2008). These changes have lead to more 
reliable prognostic information, improved treatment stratification and a move 
towards targeted therapy (Swerdlow et al., 2008). By including these components 
into this classification, they have become part of a worldwide standard expected in 
diagnostic medicine. These molecular techniques should now form part of the 
routine diagnostics of AML. 
Up to 40-50% of adult AML patients are classified as being cytogenetically normal 
(CN) as they display no visible chromosomal abnormality on conventional 
cytogenetic analysis. This heterogeneous group has a normal karyotype but widely 
varying epigenetics, gene expression profile (Grimwade et al., 1998, Mrózek and 
Bloomfield, 2006), phenotype, treatment response and prognosis (Schlenk et al., 
2008). In particular these gene mutations have the potential to assist in the further 
sub-classification of this heterogeneous group of AMLs. A summary of the 
commonly found gene mutations together with their locations, common 
associations and outcomes are presented in Table 1.1.  
The most common gene mutations in patients with a normal karyotype include 
those mentioned above (NPM1 and CEBPA) as well as mutation of the FMS-like 
tyrosine kinase 3 (FLT3). The combinations in which these gene mutations, in 
particular FLT3 and NPM1, occur are vital to patient outcome (Estey and Döhner, 
2006, Thiede et al., 2006). The presence of the FMS-like tyrosine kinase 3 internal 
 3 
 
tandem duplication (FLT3-ITD) mutation implies a poorer prognosis regardless of 
the other accompanying mutations. NPM1 mutations on their own (without the 
presence of a FLT3-ITD) provide a much improved prognosis (Döhner et al., 
2005). The significant impact of these mutations on patient outcome as well as the 
relative frequency of these mutations were important determining factors in the 
decision to assess for both NPM1 and FLT3-ITD mutations in combination in this 
study.  
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Table 1.1 Recently identified gene mutations in AML. 
A summary of their chromosomal location, frequency in CN AML, common associations and 
outcome including overall prognostic impact (Mrózek and Bloomfield, 2006). 
 
Gene Symbol Location Frequency Associated with Outcome Prognostic 
Impact 
NPM1-mut 5q35 45-62% FLT3-ITD and 
FLT3-TKD 
NPM1-mut/ 
FLT3-wt= better 
CR, EFS, RFS, 
DFS and OS 
Favourable 
FLT3- ITD 13q12 28-34% NPM1-mut 
Level of mutant 
allele important 
Always inferior 
outcome 
Adverse 
FLT3-TKD 13q12 11-14%  Better OS Favourable 
MN1 22  Treatment failure 
Increased relapse 
risk 
Inferior RFS, 
OS 
Adverse 
EVI 1 3q26  MLL-PTD Overall poorer 
outcome 
Adverse 
WT1 11p13 ~10% NPM1-mut, MLL-
PTD, FLT3-ITD 
and CEBPA 
Induction failure Adverse 
MLL PTD 11q 5-10%  Shorter CR, and 
inferior RFS, 
DFS and EFS 
Adverse 
BAALC 
overexpression 
8q22.3  FLT3-ITD, NPM1-
wt, CEBPA-mut, 
MLL-PTD 
increased ERG 
Worse CR, 
shorter DFS, 
EFS, and OS 
Adverse 
ERG 
overexpression 
21  NPM1-mut, FLT3-
ITD 
Shorter OS Adverse 
CEBPA 
 
19q13.1 
 
15-20% 
 
Less likely to carry 
FLT3-ITD, FLT3- 
TKD and MLL 
PTD 
Better CR, EFS, 
DFS and OS 
 
Favourable 
 
Abbreviations: CN, cytogenetically normal; AML, acute myeloid leukaemia; NPM1, Nucleophosmin 
1; mut, mutant; FLT3-ITD, internal tandem duplication of the FMS related tyrosine kinase 3 (FLT3) 
gene; FLT3-TKD, mutation of the tyrosine kinase domain of the FLT3 gene; wt, wild type; CR, 
complete remission; EFS, event free survival; RFS, relapse free survival; DFS, disease free survival; 
OS, overall survival; MN1, Meningioma 1; EVI 1, Ecotropic viral integration site 1 gene; MLL-PTD, 
partial tandem duplication of the myeloid/lymphoid or mixed lineage leukaemia (MLL) gene; WT 
1, Wilms’ tumour 1 gene; CEBPA, CCAAT/enhancer binding protein (C/EBP) alpha; BAALC, brain 
and acute leukaemia gene, cytoplasmic; ERG, v-ets erythroblastosis virus E26 oncogene like 
(avian). 
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1.2 AML PATHOGENESIS 
It is generally accepted that AML blasts develop from normal myeloid blasts or 
stem cells following two forms of genetic damage, therefore requiring a double hit 
(Kelly and Gilliland, 2002). One insult induces an enhanced proliferative state and 
decreased apoptosis and the other leads to a block in differentiation by inactivating 
a master regulator of myeloid differentiation. Accordingly the genetic damage or 
mutations are classified into two classes: 
Class I Mutations: Activate signal transduction pathways such as rat sarcoma 
(RAS) which represent small GTPases, or receptor tyrosine kinases such as FLT3 
or C-kit receptor or CD117 (KIT). This constitutive activation allows for a 
proliferative advantage with clonal expansion of the affected haemopoietic 
progenitors (Kelly and Gilliland, 2002, Estey and Döhner, 2006). 
Class II Mutations: Include mutations in CEBPA, Mixed Lineage Leukaemia (MLL) 
and NPM1 that affect transcription factors or parts of the transcription co-activation 
complex resulting in the impaired differentiation (Kelly and Gilliland, 2002). 
These mutations rarely overlap within their class and most often at diagnosis of 
AML, there will be at least two of these mutations present; one from each class 
(Schlenk et al., 2008). A diagrammatic representation of the different class 
mutation in the pathogenesis of AML is presented in Figure 1.1. 
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Figure 1.1 Cooperation between different class mutations in AML pathogenesis. 
Mutations in Class I allow for clone proliferation and/or a survival advantage while Class II 
mutations allow for impaired differentiation. Often a mutation from each class may be present in 
a single clone. Adapted from (Schlenk et al., 2008). 
 
1.3 NUCLEOPHOSMIN MEMBER 1 PROTEIN (NPM1) 
1.3.1 OVERVIEW OF NPM1 
NPM1 is ubiquitously expressed and is a highly conserved phosphoprotein (Rau 
and Brown, 2009). Although predominantly found in the nucleolus, it shuttles, 
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continuously between the nucleus and the cytoplasm (Borer et al., 1989). It has a 
role in various cellular processes including acting as a molecular chaperone 
(Szebeni and Olson, 1999), being involved in ribosome biogenesis and assisting in 
the regulation of centrosome duplication and therefore maintenance of genomic 
stability (Herrera et al., 1995, Yu et al., 2006). NPM1 is also capable of binding to 
several proteins such as  tumour protein 53 (TP53/p53) and the proteins which 
interact with and regulate p53 e.g. alternative reading frame (p19ARF), Human 
oncoprotein murine double minute (HMDM2) and the retinoblastoma protein (Rb) 
(Grisendi et al., 2006, Mrozek et al., 2007).  
It has recently been shown that NPM1 mutations are the most common genetic 
lesions detectable in AML (Noguera et al., 2005). These occur on chromosome 
5q35, at exon 12 (Figure 1.2), and are somatic frame shift mutations, which are 
almost always heterozygous in nature.  
 
 
Figure 1.2 NPM1 gene structure. 
This gene is found on Chromosome 5q35 and is frequently mutated in AML. The mutations (A-F) 
usually occur at exon 12. Green indicates the 3’ and 5’ and other untranslated regions. Adapted 
from (Falini et al., 2005). 
 
The mutation leads to two important changes, which act together and results in the 
aberrant cytoplasmic expression of NPM1 as demonstrated in Figure 1.3 (Falini et 
al., 2005). These changes are the loss of tryptophan residues 288 and 290 (which 
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is required for NPM1 binding to the nucleoli) and the formation of an additional 
nuclear export signal (NES) motif at the C terminus of the mutant proteins. The 
NPM1mutant (NPM1-mut) proteins recruit the NPM1 wild type (NPM1-wt) from the 
nucleoli by means of dimerization and so also affect NPM1-wt functioning.  
 
 
Figure 1.3 Mutation induced changes in the NPM1 protein. 
NPM1-wt protein is depicted in (A) with the nuclear localization signals, tryptophan 288 and 290 
present at the C-terminus. With an NPM1-mut (B) there is the creation of a new nuclear export 
signal and the loss of the nuclear localization signal. This results in increased nuclear export and 
aberrant cytoplasmic expression of the NPM1-mut. Adapted from (Falini et al., 2009). 
 
To date a total of 55 NPM1 mutations has been described. These mutations 
represent either simple 4bp insertions or more complex deletion insertion 
mutations (Schnittger et al., 2009). Mutation A, a duplication of a TCTG 
tetranucleotide at position 956 to 959 of the reference sequence accounts for 75-
85% of the mutations found. B and D mutations make up a further 10% and 5% 
respectively (Falini et al., 2005). These mutations include 4-bp insertions at 
position 960, which are distinct from each other and result in the same frame shift 
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mutation as that seen in mutation A. Mutation B has a CATG tetranucleotide 
insertion at position 956 to959 while Mutation D has a CCTG tetranucleotide 
insertion at the same position (Schnittger et al., 2009). Table 1.2 demonstrates the 
NPM1 wild type sequence as well as 8 of the common mutant variants. In 
paediatric cases, mutation A, only accounts for 11-50% of NPM1 mutation positive 
cases, while the other variants occur more frequently (Cazzaniga et al., 2005, 
Brown et al., 2007). 
 
 
Table 1.2 Wild type NPM sequence aligned with 8 of the common mutant variants. 
The red type indicates the nucleotide insertions seen in these mutations (Falini et al., 2005). 
 
Type of 
Mutation: 
Sequence: 
Wild Type GATCTCTG····GCAGTGGAGGAAGTCTCT TTAAGAAAATAG 
Mutation A GATCTCTGTCTGGCAGTGGAGGAAGTCTCTTTAAGAAAATAG 
Mutation B GATCTCTGCATGGCAGTGGAGGAAGTCTCTTTAAGAAAATAG 
Mutation C GATCTCTGCGTGGCAGT····GGAGGAAGTCTCTTTAAGAAAATAG 
Mutation D GATCTCTGCCTGGCAGTGGAGGAAGTCTCTTTAAGAAAATAG 
Mutation G GATCTCTGTTTGGCAGTGGAGGAAGTCTCTTTAAGAAAATAG 
Mutation H GATCTCTGCTTGGCAGTGGAGGAAGTCTCTTTAAGAAAATAG 
Mutation I GATCTCTGTAAGGCAGTGGAGGAAGTCTCTTTAAGAAAATAG 
Mutation J GATCTCTGTATGGCAGTGGAGGAAGTCTCTTTAAGAAAATAG 
 
Abbreviations: NPM1, Nucleophosmin 1; mut, mutation 
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1.3.2 NPM1 AND ITS ASSOCIATION WITH OTHER MUTATIONS 
NPM1 mutations occur in approximately 27-35% of all adult patients with AML and 
more specifically in 50-60% of adult CN AML making them the most frequent 
genetic abnormality in this group (Falini et al., 2005). In paediatric patients with 
AML approximately 7.5% will have an NPM1-mut, with the incidence increasing as 
age increases (Cazzaniga et al., 2005, Brown et al., 2007). This mutation is also 
found, at a lower frequency in adult Asian populations as compared to that found 
in European and American studies (Koh et al., 2009). This mutation occurs in 15% 
of AMLs with other chromosomal aberrations, especially trisomy 8 and deletion 9q 
(Thiede et al., 2006). Although uncommon there have been various reports 
confirming that NPM1 mutations can also accompany a recurrent chromosomal 
translocation such as t(8;21) or t(15;17) (Suzuki et al., 2005, Verhaak et al., 2005, 
Thiede et al., 2006). A recent study by Haferlach et al concludes that any 
chromosomal aberrations accompanying an NPM1 mutation are secondary 
events. The NPM1 mutation is always the primary event (Haferlach et al., 2009) 
and the secondary aberrations do not appear to affect prognosis (Falini et al., 
2009a, Haferlach et al., 2009). NPM1 mutations and its associations with other 
defined mutations are summarised in Table 1.3. 
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Table 1.3 Other mutations associated with NPM1-mut positivity. 
Some mutations are commonly associated and others rarely associated with NPM1 mutations. 
Other mutations have not been found to correlate with NPM1-mut positivity (Döhner et al., 2005, 
Verhaak et al., 2005). 
 
 
NPM1  
Mutation  
Positive 
Commonly 
Associated 
Rarely Associated No Correlation to 
Date 
CN MLL-PTD KIT 
Trisomy 8 Recurrent Translocations e.g. t(8;21), 
t(15;17), inv(16) 
TP53 
Del 9q CEBPA KRAS 
FLT3-ITD  NRAS 
FLT3-TKD   
Abbreviations: NPM1, Nucleophosmin 1; mut, mutation; CN, cytogenetically normal; MLL-PTD, 
partial tandem duplication of the myeloid/lymphoid or mixed lineage leukaemia (MLL) gene; KIT, 
C-kit receptor; inv, inversion; TP53, tumour protein 53; Del, Deletion; CEBPA, CCAAT/enhancer 
binding protein (C/EBP) alpha; KRAS, Kirsten rat sarcoma 2 viral oncogene homologue; FLT3-ITD, 
internal tandem duplication of the FMS related tyrosine kinase 3 (FLT3) gene; NRAS, 
Neuroblastoma RAS viral oncogene homologue; FLT3-TKD, mutation of the tyrosine kinase 
domain of the FLT3 gene. 
 
1.3.3 NPM1 CHARACTERISTIC FINDINGS  
In general, AML with mutated NPM1 is a de-novo AML which has been associated 
with certain characteristic findings. These include a normal karyotype, association 
with a FLT3-ITD mutation, decreased or absent CD34 and CD133 surface 
expression, higher bone marrow blast counts, leucocytosis, higher platelet counts, 
a higher median age at presentation and a higher frequency in female patients 
(Thiede et al., 2006). NPM1 mutations have been associated with all FAB 
morphologic subtypes of AML but are particularly common in acute 
myelomonocytic leukaemia (AML M4) and acute monoblastic and monocytic 
leukaemia (AML M5). This particular association has been found both 
morphologically and immunophenotypically with higher expression of monocytic 
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differentiation associated antigens present on flow cytometric analysis (Schnittger 
et al., 2005).  More, recently this mutation has also been associated with a 
distinctive gene expression as determined by gene expression microarray analysis 
and micro ribose nucleic acid (microRNA) profiles. A group of 42 NPM1 mutation 
negative cases was compared to 55 NPM1 mutation positive cases. These two 
AML were clearly delineated by analysis of the top 500 differentially expressed 
genes (Haferlach et al., 2009).  
 
1.3.4 NPM1 AND ITS ROLE IN LEUKAEMOGENESIS AND PATIENT 
OUTCOME 
To date, the exact role of NPM1 mutations in leukaemogenesis has remained 
uncertain. The NPM1-muts delocalizes p19 ARF, an important tumour suppressor 
gene (TSG) to the cytoplasm through its binding to the mutant NPM1 (den Besten 
et al., 2005). As a result p19ARF is not available to interact with HMDM2 in the 
nucleoplasm and thus prevents p53 initiation with a resultant compromised p53 
dependent cell cycle arrest at G1/S (Colombo et al., 2006). It is also known to 
cause an increase in the oncoprotein cMYC which may also contribute to its 
leukaemogenic effect (Di Micco et al., 2006, Rau and Brown, 2009). This is 
demonstrated in Figure 1.4. 
The presence of an NPM1 mutation in AML confers a better prognosis with a good 
response to induction chemotherapy (Thiede et al., 2006). This mutation is 
associated with improved complete remission (CR) post induction therapy as well 
as improved overall survival (OS), disease free survival (DFS), event free survival 
(EFS) and relapse free survival (RFS) provided that no concomitant FLT3-ITD 
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mutation is present. With FLT3-ITD absent, NPM1 mutation positive AML has a 
similar outcome to core binding factor (CBF) AML and CEBPA mutations i.e. a 
very favourable prognosis (Preudhomme et al., 2002).  
 
 
Figure 1.4 Role of NPM1mut in AML pathogenesis. 
NPM1mut delocalises p19ARF to the cytoplasm and as a result is no longer available for 
interaction with HMDM2 in the nucleus. This then affects p53 functioning. 
Abbreviations: NPM1, Nucleophosmin 1; mut, mutation; wt, wild type;  p53, tumour protein 53; 
AML, Acute Myeloid Leukaemia; p19ARF, p19 alternative reading frame; HMDM2, human 
oncoprotein murine double minute. 
 14 
 
1.3.5 NPM1 DETECTION 
There are various methods to detect the presence of an NPM1 mutation. One of 
the most commonly used is that of immuno-histochemisty to detect the presence 
of aberrant cytoplasmic NPM1 and thereby the presence of a gene mutation. 
Immuno-histochemisty can however be difficult to interpret especially in blasts with 
a high nuclear to cytoplasmic ratio. Recently polymerase chain reaction (PCR) 
based capillary electrophoresis methods have increased in popularity as these are 
more sensitive than immuno-histochemisty, with diagnostic sensitivity approaching 
100% (Martelli MP et al., 2008, Szankasi et al., 2008, Wertheim and Bagg, 2008). 
PCR and immuno-histochemical staining often make use of paraffin embedded 
samples as the starting material. The PCR based method can also use other 
materials e.g. peripheral blood or bone marrow aspirate (BMA) slides as the 
starting material. NPM1-mut detection as a tool for minimal residual disease 
(MRD) is a very real possibility. Not only is it a relatively frequent but also a 
relatively stable mutant. The use of quantitative PCR (QPCR) assays appears to 
be the method of choice in this regard (Gorello et al., 2006, Falini et al., 2007).  
 
1.4 NPM1 AND FLT3 MUTATIONS 
Up to 40% of patients with an NPM1 mutation also have a FLT3-ITD mutation, 
which is, twice as common in NPM1 mutation positive patients when compared to 
those with NPM1-wt (Thiede et al., 2002). The presence of a FLT3-ITD overrides 
the good prognosis of the NPM1 mutation positivity. Several studies, including that 
by Thiede et al confirmed that the NPM1 mutations are the primary events that 
preceded the acquisition of FLT3-ITD or any of the other mutations (Thiede et al., 
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2002). This is supported by the observation that in some cases there are several 
FLT3-ITDs, while only one NPM1 mutation could be found. Furthermore, the 
available evidence suggests that NPM1 mutation positive AML with an abnormal 
karyotype has similar characteristics and prognostic outcome as NPM1 mutations 
in CN AML (Haferlach et al., 2009). It can then be suggested that all three of these 
determinants i.e. the presence of FLT3-ITD, NPM1 gene mutation status and 
cytogenetic evaluation interact in such a manner that the determination of the 
presence or absence of all three of these parameters are important and dependent 
on each other for patient outcome.  
At present, within the international community, only once the diagnosis of a normal 
karyotype AML has been made will the assessment for NPM1 mutations and 
FLT3-ITD be established. With this approach, approximately 25% of AML patients 
will be excluded from testing due to the failure of cytogenetic analysis. This would  
prevent the assignment of the favourable genotype NPM1-mut/FLT3 wild type 
(FLT3-wt) if a chromosomal aberration or failed cytogenetic testing occurred 
(Mrózek et al., 2007, Reindl et al., 2006). It may therefore be more beneficial to 
patients not to recommend this hierarchy of testing and rather that all patients, at 
the time of diagnosis of AML are tested for the presence of both NPM1 and FLT3-
ITD gene mutations. Once the presence or absence of these mutations has been 
confirmed appropriate therapeutic strategies can then be implemented.  
 It is currently recommended, given the favourable prognosis of AML with NPM1 
mutation and no FLT3-ITD (NPM1-mut/FLT3-wt) that these patients are treated 
with conventional chemotherapy regimens (with or without autologous 
transplantation). They do not appear to gain from allogeneic transplant (Döhner et 
al., 2005, Schlenk et al., 2008, Rau and Brown, 2009). 
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1.5 FMS-LIKE TYROSINE KINASE 3 (FLT3) 
1.5.1 OVERVIEW OF FLT3 
The FLT3 gene is located at chromosome 13q12 and consists of 24 exons. It 
encodes a class 3 receptor tyrosine kinase which is important for haemopoietic 
progenitor cell differentiation and proliferation (Rosnet et al., 1991, Stirewalt and 
Radich, 2003, Döhner, 2007). 
FLT3 has two domains in which mutations are found and both result in increased 
signal transduction (Figure 1.5). The first is the juxtamembrane domain (JMD), 
vital for normal kinase auto inhibition and demonstrates ITDs or rarely point 
mutations. The second domain is the activation loop of the tyrosine kinase domain 
(TKD) which demonstrates point mutations (Fröhling et al., 2002). 
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Figure 1.5 FLT3 structure. 
The juxtamembrane domain is the area in which the internal tandem duplications are found. 
Point mutations are located in the second kinase domain. Adapted from (Kottaridis et al., 2003). 
 
Abbreviations: FLT3, FMS related tyrosine kinase 3 gene 
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1.5.2 FLT3-ITD 
FLT3-ITD in AML is quite diverse in both size and location. It occurs at the 5’ end 
of the JMD in exons 14 and 15 (Nakao et al., 1996, Kottaridis et al., 2003); this 
mutation can vary in length from 3 to 400 nucleotides and is always in frame 
(Schnittger et al., 2002). FLT3-ITD produces an abnormal protein with resultant 
autophosphorylation, ligand-independent receptor dimerization and constitutive 
activation, which in turn allows for downstream signalling pathways to be 
activated. These include the Janus kinase 2 (JAK2), signal transducer and 
activator of transcription 5 (STAT5) pathway and the mitogen activated protein 
kinase (MAPK) pathway (Choudhary et al., 2005, Reindl et al., 2006). 
FLT3-ITD is found in all forms of AML (20-40% of all cases) but, mostly in CN AML 
and also AML with t(6;9) and t(15;17) (Kottaridis et al., 2003, Slovak et al., 2006). 
With acute promyelocytic leukaemia (AML M3/APL), FLT3-ITDs presence can 
range from 30-39% of cases. Variant APL, however, is most often FLT3-ITD 
positive (up to 65-80% of cases). This increased propensity for FLT3-ITD positivity 
in variant AML M3, together with the common finding of leucocytosis and the 
shorter breakpoint cluster region 3 (BCR3) found in atypical APL suggests that 
these features may all have a common causative pathology (Noguera et al., 2002, 
Kottaridis et al., 2003). 
In paediatric cases the frequency of occurrence of this mutation appears to be 
much lower, approximately 5-16.5% (Krstovski et al., 2009), although the clinical 
characteristics and outcome appear to be similar to those seen in adults (Zwaan et 
al., 2003). 
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1.5.3 FLT3-ITD CHARACTERISTIC FINDINGS 
FLT3-ITDs are commonly associated with a leucocytosis, increased blast 
percentage in both the peripheral blood and bone marrow and with an increased 
lactate dehydrogenase (LDH) (Kottaridis et al., 2003, Döhner et al., 2005). Several 
studies have reported an association of this mutation with FAB M3 and FAB M5 
and in particular acute monocytic leukaemia (AML M5b) (Schnittger et al., 2002, 
Thiede et al., 2002). Some patients (9-23%) will have more than one ITD mutation 
present. In general this has been found to range between two to five additional 
bands and may reflect underlying genetic instability (Kottaridis et al., 2001, 
Noguera et al., 2002, Kottaridis et al., 2003). 
 
1.5.4 FLT3-ITD AND ITS ASSOCIATION WITH OTHER MUTATIONS 
FLT3-ITD and its association with other mutations is summarised in Table 1.4. 
CEBPA does not seem to have any association with FLT3-ITD positivity 
(Preudhomme et al., 2002). While mixed lineage leukaemia partial tandem 
duplication (MLL-PTD) gene abnormalities may be associated, it is difficult to 
assess due to the low frequency of this in patients with AML. In general both MLL-
PTD and FLT3 duplications are more commonly found in patients with a normal 
karyotype (Kottaridis et al., 2003). FLT3-ITD mutations has also been found in 
patients with t(8;21) and inv(16); these are considered in the Class II category of 
mutations (Kottaridis et al., 2001, Thiede et al., 2002, Schnittger et al., 2002). 
FLT3-ITD mutations have occasionally been found in patients with complex 
cytogenetics, including 11q23 and t(3;3). Neuroblastoma RAS viral oncogene 
homologue (NRAS) mutations and FLT3-ITD are found in combination in 
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approximately 0-4% of patients. This suggests that if both of these genes are 
mutated e in the same clone there will be no additional advantage to the clone 
(Kottaridis et al., 2003, Stirewalt and Radich, 2003). 
 
Table 1.4 Other mutations associated with FLT3-ITD positivity. 
Some mutations are commonly associated and others rarely associated with FLT3-ITD. Other 
mutations have not been found to correlate with FLT3-ITD (Kottaridis et al., 2003). 
 
 
 
FLT3-ITD 
Mutation 
Positive 
Commonly Associated Rarely Associated No Correlation to date 
CN  11q23 CEBPA 
t(15;17) esp. vM3 t(3;3) MLL-PTD 
t(6;9) t(9;11)  
t(8;21) t(9;22)  
inv(16) NRAS  
NPM1   
 
 Abbreviations:  FLT3-ITD, internal tandem duplication of the FMS related tyrosine kinase 3 (FLT3) 
gene; CN, cytogenetically normal; CEBPA, CCAAT/enhancer binding protein (C/EBP) alpha; vM3, 
variant acute promyelocytic leukaemia; MLL-PTD, partial tandem duplication of the 
myeloid/lymphoid or mixed lineage leukaemia (MLL) gene;  Inv, Inversion; NRAS, Neuroblastoma 
RAS viral oncogene homologue; NPM1, Nucleophosmin 1 
 
1.5.5 FLT3-ITD AND PATIENT OUTCOME    
Patients with the FLT3-ITD in CN AML differ from those without this gene mutation 
with regards to both pre-treatment characteristics and treatment outcome, which is 
much inferior. This has been seen for EFS, RFS and OS (Mrózek et al., 2007). 
Further evidence confirms that the level of the mutant allele or ratio of wild type to 
mutant plays an important role in determining patient outcome (Whitman et al., 
2001). Furthermore, a recent report has found that FLT3-ITD status was a 
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prognostic marker in monocytic lineage AML and that cytogenetics was not (Koh 
et al., 2009).   
 
1.5.6 FLT3-ITD AT PRESENTATION AND RELAPSE   
There have been various studies to assess the presence of FLT3-ITD mutations at 
presentation and relapse. In a recent review, assessment of three of these studies, 
found that 86% of these patients maintained their original FLT3-ITD positive status 
at presentation and at relapse. A proportion of patients were found to either gain 
(10.1%) or lose (3.9%) a FLT3-ITD mutation at relapse. This not only prevents the 
use of FLT3-ITD mutations as a marker for assessment of MRD but also implies 
that the FLT3-ITD mutation is indeed a secondary event in leukaemogenesis 
(Kottaridis et al., 2001, Kottaridis et al., 2003). Further support for the theory of 
FLT3-ITD mutations as the second hit is the fact that these mutations are often 
only present in a subpopulation of the leukaemic cells.   
All of the above is relevant for further elucidation of this mutation in its role in 
leukaemogenesis, patient outcome and current and future treatment strategies. It 
also confirms the need for this mutations detection to become part of the routine 
diagnostic work up in AML, just as cytogenetics has become a routine 
requirement. 
 
1.5.7 FLT3-ITD DETECTION 
There are various means to detect a FLT3-ITD mutation. One of the commonly 
used methods is standard PCR amplification with visualisation on agarose gel by 
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means of ethidium bromide. This technique does however have limitations, some 
of which include its qualitative nature, the need for increased amount of 
deoxyribose nucleic acid (DNA), its inability to detect both mutations 
simultaneously and the potential interpretative difficulty when assessing a mutant 
and a wild type which differ by only a few base pairs (bp) (Gleissner et al., 2001). 
For these reasons capillary electrophoresis is favoured. FLT3-ITD detection as 
part of an assessment for minimal residual disease detection has proved 
unsuccessful to date. FLT3-ITD is considered a second hit and does not show 
stability throughout the disease process (Kottaridis et al., 2003). 
 
1.6 MOLECULAR TARGETS IN THERAPY 
1.6.1 OVERVIEW OF MOLECULAR THERAPY IN AML 
Traditional therapy, has improved significantly in AML in general, with new drugs 
such as monoclonal antibodies and all trans retinoic acid (ATRA) coming to the 
fore. This together with improved stem cell transplant protocols has made a 
significant difference to the outcome of patients with AML (Sanz et al., 2009). But, 
despite these advancements, there is still a need for greater improvement and it 
appears as if molecular targeting may be the answer. 
Since the first identification of molecular changes and gene expression in AML, 
research and resources have been focused on finding new molecular markers; 
determining their interaction and understanding their pathobiology. Ideally 
individual targeted therapy, based on the underlying molecular abnormality is 
sought and currently, various trials and research are underway. Tyrosine kinase 
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inhibitors (TKIs) are candidate agents under investigation for the inhibition or 
inactivation of FLT-3 mutants (Cools et al., 2004, Sanz et al., 2009). 
 
1.6.2 TYROSINE KINASE INHIBITORS (TKIS) 
FLT3 gene mutations are characterized by aberrant tyrosine kinase activity with 
the constitutive activation of FLT3 in the absence of its ligand (Blum and Marcucci, 
2008, Tam and Gilliland, 2008). TKIs do show some effectiveness, predominantly 
in the decrease of peripheral blasts. Bone marrow blasts appear to receive growth 
factor support from their micro-environment, thus decreasing the effectiveness of 
FLT3 inhibitors (Parmar et al., 2011). The overexpression of the FLT3 protein 
secondary to the presence of and in response to kinase inhibitors may contribute 
to the clinical resisitance seen  (Weisberg et al., 2011). Mobilization of blasts into 
the peripheral blood prior to FLT3 inhibitor administration might be a viable 
solution to this problem (Tam and Gilliland, 2008). 
Another option to improve current treatment outcomes may be to genotype all 
patients and thereby predict a response before deciding to initiate this form of 
therapy at all (Tam and Gilliland, 2008) . Alternatively new compounds may need 
to be developed to overcome any resistance mutations (Davies et al., 2011). In the 
interim, combination therapy is likely to become the standard of care, especially 
with recent studies showing that combination therapy decreases toxicity and 
increases responses (Wang et al., 2011, Wiernik, 2011). 
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The importance of these gene mutations with regard to patient outcome and 
potential management have become evident and formed the basis for the 
objectives of this report. 
 
1.7 OBJECTIVES OF THIS RESEARCH REPORT 
The primary aim of this research report was to assess for the presence of NPM1 
and FLT3-ITD mutations in patients diagnosed with de novo AML at a single 
academic centre. In order to achieve this aim the following objectives were 
completed:  
• The establishment of a detection method for both NPM1 and FLT3-ITD 
mutations by means of PCR.   
• Determine the overall number of these mutations in the study population; 
assess the frequency of these mutations alone and in combination as well 
as assessing the distribution of these mutations in the various population 
subgroups. 
• Correlate with immunophenotypic analysis of the samples and other routine 
parameters. These routine parameters included the haemoglobin (Hb), 
white cell count (WCC), platelet count and blast count at diagnosis.   
• Furthermore, a comparison to the available literature was made to assess 
whether the patient profile found in our study compares with that found in 
other population groups. 
The epidemiology and patient demographics of those adult patients diagnosed 
with de novo AML in South Africa has to the best of our knowledge, not been 
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recently assessed. This study provided all the necessary data to assess this 
particular patient group’s characteristics and how these may differ from that seen 
in the developed world.  
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2 MATERIALS AND METHODS 
2.1 SAMPLES 
Patients diagnosed with de novo AML at Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) were included into a database covering the period 
from September 2004 to December 2009. Diagnostic information and any other 
relevant information was extracted from the National Health Laboratory Services 
(NHLS) laboratory information system. Specimens were collected retrospectively 
from these cases. These consisted of peripheral blood smears, peripheral blood 
anti-coagulated with ethylenediaminetetraacetic acid (EDTA) or BMA samples. 
The material used was considered to be for storage and did not jeopardise routine 
diagnostic analysis. Negative control samples were randomly chosen from patients 
who were admitted to CMJAH and at the time had either a near normal full blood 
count (FBC) or a BMA assessment which showed no malignant infiltrate and no 
overt pathology. All specimens used as negative control samples were intended 
for the purpose of routine monitoring and/ or diagnosis and only the material 
remaining after routine analysis was utilised. 
All cases that were diagnosed before 2008 (2004-2007) were classified as per the 
criteria stipulated by the WHO Classification of Tumours of Haematopoietic and 
Lymphoid Tissues that were published in 2001 (Jaffe et al., 2001) and those cases 
diagnosed from 2008 onwards were classified as per the criteria stipulated by the 
updated WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues  
(Swerdlow et al., 2008). Ethical approval was obtained from the University 
(No.:MO90734) for the extraction of material and use of patient data.  
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2.2 DNA EXTRACTION 
DNA was extracted from bone marrow aspirate slides, peripheral blood slides or 
EDTA collected peripheral blood using High Pure PCR template Preparation Kit 
(Roche, Mannheim, Germany) as per the manufacturer’s instructions and as per  
the institutional Standard Operating Procedure (SOP: HAE0296v3) in the PCR 
laboratory. Blood wash (100-150µl) was used to remove blood and bone marrow 
from sample slides. Binding buffer (200 µl) and proteinase K (40µl) was then 
added to the sample material and incubated at 72˚C for 10 minutes (min). 
Isoproponol (100µl) was added and the sample then centrifuged at 8000rpm for 
1min. An amount of 500µl inhibitor removal buffer was added to the sample which 
was again centrifuged at 8000rpm for 1min. On 2 separate occasions 500µl wash 
buffer was added and samples centrifuged as above. The samples were 
centrifuged at 14000rpm for 10 seconds to remove the remaining wash buffer from 
the sample.  Finally pre-warmed (70˚C) elution buffer (40-50µl) was added to the 
filter tube and centrifuged at 8000rpm for 1min.  
 
2.3 DNA QUALITY 
Once samples were extracted the DNA quality and quantity was determined. This 
was performed making use of the NanoDrop® ND-1000 (NanoDrop Technologies 
Wilmington, Delaware USA). Both the DNA concentration and 260/280 value was 
recorded. This was done using ultraviolet spectrophotometry and measuring the 
ratio of absorbance at 260nm and 280nm.  The samples were considered to be of 
good quality if the 260/280 ratio was between 1.8 and 2.0.  If the sample yielded 
an undesirable result and more of the same sample was available, it was re-
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extracted. If however, no further sample was available for re-extraction the already 
extracted samples  still underwent electrophoresis and the result was interpreted 
provided that the internal controls were present. 
 
2.4 PCR FOR FLT3-ITD AND NPM1 MUTATIONS 
PCR primer sets used to detect the presence or absence of FLT3-ITDs and the 
NPM1-mut have been previously described by Kottaridis et al (Kottaridis et al., 
2001) and Falini et al (Falini et al., 2005) respectively. Primers for FLT3-ITD span 
approximately 330bp and include the common internal duplication site. The primer 
sets for NPM1 span approximately 170bp and cover mutations from A-F and thus 
cover the majority of described mutations(Huang et al., 2008). All of the primer 
sets were obtained from Integrated DNA Technologies and reconstituted 
according to instructions on the package insert. These primer sets and their 
sequences are presented in Table 2.1. 
 
 
 
Table 2.1 Specific primer sequences of FLT3, NPM1 and HBG used. 
 
Name  Primer Sequence 
FLT3-F  Forward Primer FLT3 5’FAM- AGCA ATT TAG GTA TGA AAG 
CCA GCTA – 3’ 
FLT3-R  Reverse Primer FLT3 5’-CTT TCA GCA TTT TGA CGG CAA 
CC – 3’ 
NPM1-F  Forward Primer NPM1 5’-GTT TCT TTT TTT TTT TTT CCA 
GGC TAT TCA AG-3’ 
NPM1-R  Reverse Primer NPM1 5’-HEX CAC GGT AGG GAA AGT TCT 
CAC TCT GC – 3’ 
 
Abbreviations: NPM1, Nucleophosmin member 1 protein; FLT3-ITD, internal tandem duplication 
of the FMS related tyrosine kinase 3 (FLT3) gene; F, forward; R, reverse  
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The PCR conditions initially used were those described by Huang et al (Huang et 
al., 2008)  making use of the C1000 thermal cycler (Bio-Rad Laboratories Inc, 
Hercules, CA ) .   
The C1000 thermal cycler (Bio-Rad Laboratories Inc, Hercules, CA ) was used to 
perform the reaction and the PCR conditions used were as follows: initial 
denaturing for 10min at 95˚C, followed by 45 cycles at 95˚C for 20s, 60˚C for 60s 
and 72˚C for 60s and a final cycle of 30min at 72˚C. These conditions were used 
for both the NPM1 and FLT3 assays.  
The PCR conditions described and the master mix as set out below in Table 2.2 
was to be the standard operating procedure for the rest of the research 
assignment.  The PCR products were then diluted to 1:10 and 1:30 and each of 
these electrophoresed on a 2% agarose gel (Bioline Ltd, London, UK) to assess 
for the presence of the appropriate PCR product and then analysed by means of 
capillary electrophoresis. 
 As presented in a multiplex method used by Huang et al, (Huang et al., 2008) 
200ng of DNA was used per reaction. In order to obtain this amount of DNA the 
following calculation was used: 200ng/ 80ng/µl = 2.5µl of DNA per reaction 
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Table 2.2 PCR master mix protocol. 
The multiplex PCR was discarded and each primer set was incorporated into its own individual 
master mix. 
 
Product Amount 
Genomic DNA 2.5 µl 
Primers: 
NPM1-F /NPM1-R 
FLT3-F /FLT3-R 
 
20pmol (0.5 µl) Forward/ 20pmol (0.5 µl) Reverse 
20pmol (0.5 µl) Forward/ 20pmol (0.5 µl) Reverse 
MgCl2 25mmol/l (2.0 µl) 
dNTP 2.5mmol/l (0.75 µl) 
10xPCR buffer 1.35 µl 
Amplitaq Gold  0.5 µl (2.5U) 
Water 11.9 µl 
 
Abbreviations: NPM1, nucleophosmin; FLT3, FMS related tyrosine kinase 3; MgCl2, magnesium 
chloride; dNTP, deoxynucleotide triphosphates; F, forward; R, reverse. 
 
2.5 GEL ANALYSIS 
A 50ml 2% agarose gel was prepared using 50ml 1x trisborate EDTA (TBE) buffer 
in a 250ml conical beaker. Once the gel had been mixed and heated and allowed 
to cool to 60-70˚C 2.5ul ethidium bromide (10mg/ml) was added. The gel was 
poured into a caste and allowed to set. The samples were then loaded together 
with a suitable size marker (e.g. 50bp Ladder or Low molecular weight marker).  
The gel was then placed in the gel tank in 1xTBE buffer with ethidium bromide at 
150 volts. The gel was electrophoresed until the dye was approximately ¾ down 
the gel (1 hour).  Following electrophoresis, the gel was visualised under UV light 
and a photograph taken. The presence of a band at approximately 330bp indicates 
the presence of FLT3-wt and at approximately 170bp NPM1-wt. 
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2.6 CAPILLARY ELECTROPHORESIS ANALYSIS 
All samples were analysed by capillary electrophoresis on an ABI 3130 Genetic 
Analyser (Applied Biosciences, Inc., Foster City, CA). The labelled PCR product 
samples were diluted to 1:10 and 1:30 with distilled water. Of these dilutions 1µl 
was mixed with 8.5µl of HiDi formamide (Applied Biosystems, Inc., Foster City, 
CA) and 0.5µl of Genescan ROX 350 internal size standards (Applied Biosystems, 
Inc., Foster City, CA) and loaded in 96 well plates. This sample preparation is 
demonstrated in Table 2.3. These samples were then heated to 95˚C for 2min and 
then snap chilled on ice for 5min directly afterwards. The samples were then 
separated by means of the capillary electrophoresis based system on the 3130 
Genetic Analyser using the POP7™ conformation analysis polymer (Applied 
Biosystems, Inc., Foster City, CA) and the fragment analysis default method as 
per the manufacturer’s instructions. The raw data was then analysed using the 
GeneMapper version (v) 2.0 software (Applied Biosystems, Inc., Foster City, CA). 
All cases with a mutant peak present were included for analysis, including those 
with a mutant peak <100. 
 
Table 2.3 PCR product preparation for capillary electrophoresis analysis. 
Standard volumes of ROX™ Size Standard and HiDi™ Formamide are used. 
 
Solution Volume 
ROX™ Size Standard 0.5 µl 
Hi Di™ Formamide 8.5 µl 
PCR product 1.0 µl 
Total  10 µl 
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Reproducibility of the assay was assessed by means of repeating random 
(controls and mutation positive) samples as duplicated on separate days in order 
to determine if the expected peak size was maintained. 
 
2.7 DILUTIONAL ASSESSMENT 
Samples with known mutation positivity (NPM1-mut and FLT3-ITD respectively) 
were serially twofold diluted making use of extracted wild type DNA from a control 
sample. The NPM1 and FLT3 fragments were amplified as described above and 
the PCR products analysed by capillary electrophoresis. This was performed in 
attempt to assess the sensitivity of the assay. 
Another twofold serial dilution making use of distilled H2O as the diluent was 
performed in a similar manner as described above. This was performed in order to 
assess the robustness of the assay. 
 
2.8 FLT3 MUTANT LEVEL ASSESSMENT 
The area under the curve (AUC) of both the mutant and wild type FLT3 peak 
generated on capillary electrophoresis is automatically recorded as part of the 
electropherogram data. The relative mutant level is then calculated using the AUC 
of the mutant and expressed as a percentage of total FLT3. The calculation is as 
follows: AUC FLT3-ITD x100/ AUC FLT3-wt +AUC FLT3-ITD (Gale et al., 2008). 
Refer to Appendix 5.1 for further details.  
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2.9 IMMUNOPHENOTYPIC ANALYSIS OF AML BY MEANS OF A PANEL OF 
ANTIBODIES 
2.9.1 SAMPLE PREPARATION 
Samples were prepared for immunophenotypic analysis by using accredited 
standard operating procedures for immunophenotypic preparation (SOP: 
HAE0066) as described below in the routine laboratory.  
2.9.1.1 ENRICHMENT OF MONONUCLEAR CELLS 
Samples were layered onto 4.5ml of Histopaque® (Sigma-Aldrich Inc., St. Louis, 
MO) and then centrifuged at 3500rpm for 15min. This concentrates mononuclear 
cells into a single layer. The enriched mononuclear cell layer was pipetted into a 
new tube and washed in phosphate buffered saline (PBS) (Oxoid Ltd, 
Basingstoke, HA). 
2.9.1.2 RED CELL LYSIS 
The ficoll prepared samples were incubated for 4min with 4ml, 8.9% isotonic 
ammonium chloride in order to lyse any remaining red cells. Debris was removed 
by washing the samples in 5ml of PBS. Finally the samples were centrifuged to 
obtain a cellular button which was then re-suspended in 1ml of PBS. Monoclonal 
antibodies were added to each tube containing 100µl of cells according to the 
manufacturer’s instructions and the tube was then incubated for 15min at room 
temperature, in the dark, after being vortexed briefly. For each slide 0.1ml of 
antibody was used for staining and a total of 5 washes were performed making 
use of PBS. 
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2.10 IMMUNOPHENOTYPING ANALYSIS FOR LEUKAEMIAS 
Immunophenotypic analysis using the accredited and validated standard operating 
procedure (SOP: HAE0042v4) was performed as part of the main laboratories 
routine work flow at the time of receiving the sample and the relevant request 
form. A number of monoclonal antibodies were added to a single tube of 100µl of 
cells in order to allow for multiparameter flow cytometry analysis. The monoclonal 
antibodies used in a particular combination were determined by the registrar or 
pathologist analysing the flow cytometry. Paint-A-Gate™ Pro software (BD 
Biosciences Inc., San Jose, CA)  was used for analysis of the results on the FACS 
Calibur (BD Biosciences Inc., San Jose, CA). Painting allows the user to select a 
group of events on a dot plot and label them with an identifying colour. The events 
painted with a particular colour on one dot plot will be labelled by Paint-A-Gate 
with the same colour on all other plots generated from that data set. Paint-A-Gate 
can display information such as the percentage of total events or the number of 
events represented by the painted population. Paint-A-Gate was used also used to 
calculate the statistics of the painted populations. An “acute screen” was 
performed on either peripheral blood or a bone marrow aspirate sample when a 
patient is suspected of having leukaemia. This consists of a panel of monoclonal 
antibodies prepared in a specific combination in order to make a clear diagnosis. 
In some instances the samples received are not sufficient to perform an acute 
screen and thus a limited analysis is done. The limited analysis may still be able to 
distinguish a myeloid leukaemia from a lymphoid leukaemia. Monoclonal 
antibodies routinely performed and with particular relevance to this study are 
summarised in Table 2.4. The monoclonal antibodies used included CD4, CD7, 
CD8, CD13, CD33, CD117 and CD45 (Beckman Coulter Inc., Pasadena, CA). 
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CD15, CD34 and myeloperoxidase (Dako, Denmark, A/S) as well as CD3, CD5, 
CD14 and anti-HLA (BD Biosciences Inc., San Jose, CA). The diagnosis of an 
AML was only made once the various criteria as stipulated in the WHO 2008 
classification had been met. 
 
Table 2.4 Monoclonal antibodies routinely used in diagnosing an AML. 
Indication of their positivity in the different French-American-British (FAB) groups  
(Bordessoule et al., 1993).  
 
Antigen FAB classification 
 M0 M1 M2 M3 M4 M5 M6 M7 
CD7 (PE) -/+ -/+ -/+ - -/+ -/+ - - 
CD11b (FITC) - - -/+ - +/- + - - 
CD13 (PE) + + + + + + -/+ -/+ 
CD14 (FITC) - - - - +/- + - - 
CD15 (FITC) +/- +/- + +/- + + - - 
CD33 (PE) + + + + + + -/+ -/+ 
CD34 (FITC) + + +/- - - - - - 
CD45 (PE) + + + + + + +/- +/- 
Glycophorin A (FITC) - - - - - - +/- - 
MPO - + + + +/- - - - 
HLA-DR (FITC) +/- +/- +/- - ++/+++ ++/+++ +/- +/- 
CD117 (PE) + + + - +/- - +/- +/- 
CD4 dim (FITC) - - - - +/- +/- - - 
Abbreviations: FAB, French American British; CD, clusters of differentiation; FITC, fluorescein 
isothiocyanate; PE, phycoerythrin; MPO, myeloperoxidase; HLA-DR, human leukocyte antigen- DR.  
 
2.11 SEQUENCING REACTION AND ANALYSIS 
In order to sequence the PCR products obtained from 3 of the FLT3-ITD mutated 
and 2 of the NPM1 mutated samples the ABI PRISM BigDye™ Terminator version 
3.1 ready reaction cycle sequencing kit was used by both the NHLS and Inqaba 
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Biotec. The initial PCR product was quantified by measuring absorption at 260nm 
using the Nanodrop Spectrophotometer. This was then followed by a DNA clean 
up step. A total of 3µl of PCR product was added to the 17µl reaction volume 
used. As demonstrated in Table 2.5, the following was prepared on ice: 
 
Table 2.5 Cycle Sequencing PCR Master Mix. 
 
Solution Volume 
Terminator ready reaction mix 2 µl 
5x buffer 4 µl 
PCR product 5.0 µl 
Primer 3.2pmol/0.1µl 6.4µl 
Deionised water 4.6 µl 
Total  10 µl 
 
The template was then mixed and spun and placed in the thermal cycler. The 
following cycling parameters were used: 96˚C for 1min, 96˚C for 10sec, 50˚C for 
5sec, 60˚C for 4min for 25 cycles and 4˚C for infinity. 
Following this, a cleanup of the cycle sequencing product takes place. This is done 
using the DyeEx® 2.0 Spin Kit (Qiagen Inc., CA, USA). This is done in order to 
remove the unincorporated dye terminators from the sequencing reaction. 
The DyeEx® 2.0 Spin Kit columns are vortexed in order to resuspend them. The 
columns are then centrifuged for 3 min at 750 xg in an Eppendorf centrifuge to 
elute the sample. The DyeEx® 2.0 Spin column is placed in a newly labelled 
microcentrifuge tube and the sample applied to the centre of the column. It is then 
centrifuged again as described above. The eluted samples are then dried for 
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35min in the miVac DNA concentrator. These dried samples are then resuspended 
in 10µl of HighDye Formamide. 
 All of the PCR products obtained  were then prepared for capillary electrophoresis  
on the ABI 3130 Genetic Analyser (Applied Biosciences, Inc., Foster City, CA) 
using the POP7™ conformation analysis polymer (Applied Biosystems, Inc., Foster 
City, CA) and the Sequence Analysis default method as per the manufacturer’s 
instructions. The samples were then analysed using the Sequence Scanner 
Software v1.0 (Applied Biosystems, Inc., Foster City, CA) and the alignment to the 
reference sequences was made using Geneious Pro 5.0 (Biomatters Ltd., 
Auckland, New Zealand). The samples being assessed for FLT3-ITD mutations 
were aligned to the Gene Bank accession number NG_00706 and the samples 
being assessed for an NPM1 mutation were aligned to the accession number 
NM_002520. 
 
2.12 CYTOGENETIC ANALYSIS 
Cytogenetic analysis was performed on bone marrow aspirate smears submitted 
by the treating doctor. The samples were prepared, in the routine laboratory, for 
analysis and interpreted by using accredited standard operating procedures for 
cytogenetic analysis and preparation (SOP: HAE0220) as described below.  
Fresh bone marrow of 1.0-2.0ml was obtained from the initial aspirate in a lithium 
heparin tube and kept at room temperature. Cultures were then initiated within 24 
hours of collection. 
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2.12.1 CULTURE INITIATION 
The specimen was centrifuged at 1500rmp for 10min at room temperature. The 
majority of the supernatant was removed with a sterile Pasteur pipette, leaving a 
small amount above the pellet. The pellet was re-suspended in the remaining 
supernatant. For the 24-48 hour culture 0.25-0.5ml of the suspension was added 
to a sterile 50ml culture flask which contains 3-5ml of complete supplemented 
medium. This was then incubated at 37°c overnight.  
2.12.2 HARVESTING PROCEDURE AND SLIDE MAKING 
The culture was centrifuged at 1500rpm for 8-10min. The supernatant was then 
removed and 0.1ml of colemid and 6ml of warm potassium chloride (37˚C) was 
added. This was then mixed and incubated for 25min at 37˚C. A total of 3 drops of 
cold 3:1 methanol acetic acid was added, mixed and the solution centrifuged at 
1500rpm for 8-10min. The supernatant was removed and the pellet re-suspended 
again. Another 5ml of cold 3:1 methanol acetic acid was added and the solution 
thoroughly mixed. The solution was again centrifuged at 1500rpm for 8-10min, the 
supernatant is removed and the pellet re-suspended and another 5ml of cold 3:1 
methanol acetic acid was added and the solution thoroughly mixed. Slides were 
then made according to the slide preparation protocol. 
2.12.3 REPORTING OF RESULTS 
The results were signed off by the head of the unit or laboratory manager and 
included a tabulation of cells analysed, their chromosome counts, karyotypes 
description by the International System for Human Cytogenetic Nomenclature 
(ISCN) (2005) system. A total of 20 metaphases were analysed. 
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2.13 FISH ANALYSIS 
FISH analysis was performed on bone marrow aspirate smears submitted by the 
treating doctor. The samples were prepared for analysis and interpreted by using 
accredited standard operating procedures for FISH analysis and interpretation 
(SOP: HAE0234 and HAE0244) as described below.  
2.13.1 SAMPLE PREPARATION 
The unstained bone marrow aspirate slides were pre-treated with methanol for 
30min at a temperature of -20˚C and then dehydrated in a series of graduated 
ethanol solutions of 70%, 90% and a 100% for 5min each at room temperature. 
The slides were then air dried at 37˚C. The slides are then warmed at 60˚C for 
5min and put into a denaturing solution for another 5min. Afterwards they are 
immediately put in ice cold ethanol solutions of 70%, 90% and a 100% for 5min 
each. The slides were then air dried in an up right position. 
2.13.2 FISH PROBES 
The probes used included the following: LSI BCR/ABL ES dual colour 
translocation probe (Vysis, Abbott, Illinois, USA), LSI PML/RARA dual colour 
translocation probe, LSI TEL/AML ES dual colour translocation probe, LSI MLL 
dual colour probe, LSI ETO spectrum orange/ LSI AML1 spectrum green, LSI CBF 
B, inv (16) dual colour probe 
The probes used were defrosted and kept in the dark and vortexed briefly before 
1µl of the probe, was mixed together in an Eppendorf tube together with 2ul of 
Sabax water and 7µl of the hybridization buffer and then spun for 5sec at 
13000rpm and vortexed.  
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The probes were then denatured at 76˚C by floating the Eppendorf tube in a water 
bath for 5min. The probe tube was put on flaked ice, immediately for 5min, then 
centrifuged again for 5sec at 13000 rpm and then put back on ice. 
The probe mixture (10 µl) was dispensed onto the slides and covered with a cover 
slip. The slides were put in a slide carrier and placed in a beaker which was then 
incubated at 37˚C overnight to allow for hybridization to take place.  
Slides were removed from the incubator and briefly dipped into 50% formamide 
and the coverslip shaken off from the slide. The slides were then washed in 50% 
formamide for 10min. This was repeated twice. 
The slides were washed in 2x salt, sodium citrate (SSC) for 10 min in a shaking 
waterbath and then washed in 2xSSC and Tween® for 5min at 42-46˚C. An 
amount of 50µl of DAPI was added to 50ml of 2xSSC at room temperature and the 
slides were put into this solution and placed on the shaker for 15min. The coplin 
jar is covered to protect it from light. The slides were then washed in Tween 
solution at room temperature for 2min. One drop of vectashield mounting solution 
was dispensed onto each slide. A large cover slip was then placed onto each 
slide. The slides were kept in the dark for analysis under fluorescent microscope.   
2.13.3 REPORTING RESULTS 
There were between 100-200 cells analysed and the findings reported as a 
percentage. The presence of a specific fusion gene was reported as a positive 
result and the absence of the fusion gene as a negative. 
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2.14 NPM1 CYTOPLASMIC STAINING 
FLEX Monoclonal Mouse Anti-Human Nucleophosmin, Clone 376, ready-to-use 
(Dako, Denmark, A/S) was used as per manufacturer’s instructions to stain 
paraffin embedded trephine samples for cytoplasmic NPM1. Trephine tissue was 
cut into sections of approximately 4 µm and pre-treated with heat induced epitope 
retrieval, using EnVision FLEX Target Retrieval Solution, High pH (Dako, 
Denmark, A/S). The pre-treatment (PT) Link Autostainer (Dako, Denmark, A/S) 
was used for this pre-treatment procedure. The pre-heat temperature was 65˚C 
which was followed by increasing the temperature to 97˚C for 20min (epitope 
retrieval temperature) and then cooling back down to 65˚C. The samples were 
then removed from the Autostainer rack and immediately dipped into the PT Link 
rinse station, which contained Envision FLEX Wash Buffer. The samples were 
then left in the wash buffer for 1-5min. The staining steps using the FLEX 
Monoclonal Mouse Anti-Human Nucleophosmin, Clone 376, ready-to-use was pre-
programmed into the Autostainer Link software (Dako, Denmark, A/S). For each 
slide 0.1ml of antibody was used for staining with an incubation time of 20min. A 
total of 5 washes were performed making use of PBS. 
  
2.15 STATISTICAL ANALYSIS 
All of the clinical features at presentation were compared according to the 
mutation status i.e. NPM1 and FLT3-ITD mutation positivity. Categorical variables 
such as sex, FAB subtype and immunophenotypic markers were compared using 
the Fischer’s exact test. The continuous variables such as age, platelet count, Hb 
and WCC were compared using the Kruskal-Wallis test and the Mann-Whitney U 
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test. These tests were performed using GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego, CA). Differences between the results of 
comparative tests were considered statistically significant if the 2-sided P value 
was less than 0.05.  
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3 RESULTS 
3.1 INTRODUCTION 
A number of experiments were performed in order to optimise the assay. This 
included assessing DNA purity and integrity as well as PCR optimisation. Various 
alternative methods were used in an attempt to prove NPM1-mut and FLT3-ITD 
positivity. This included NPM1 cytoplasmic staining and sequencing; these results 
are reported below.  Once these findings had been evaluated and reported the 
patient sample results were assessed and analysed accordingly.  
Figure 3.1 represents a summary of the samples initially identified as being AML 
positive and the various exclusion criteria which were applied. 
Of the 236 samples, 1 of these were excluded based on age at diagnosis (<17 
years), another 29 were excluded based on their initial WHO diagnosis i.e. 
transformation from myelodysplastic syndrome (MDS) or myeloproliferative 
neoplasms (MPN) or a diagnosis of biphenotypic, ambiguous or undifferentiated 
lineage leukaemia. A further 5 samples were excluded based on only having a 
disease population of <10% and lastly another 5 samples were excluded as o 
result was obtained on the assay. Of the 197 samples which were processed, 32 
were either controls or formed part of the longitudinal assessment of the 3 cases 
described in section 3.14. After the above exclusions were taken into 
consideration a total of 164 samples were available for further analysis. Of these 
164 cases were assessed immunophenotypically, 164 cases had FBC parameters 
available for comparison, 102 samples had cytogenetic or FISH results available, 
5 samples were sequenced and 32 samples with corresponding trephine samples 
available were assessed for cytoplasmic NPM1 staining. 
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Figure 3.1 Flow diagram indicating the number of samples collected, reason for exclusion and 
number of cases analysed. 
A number of these were patients with t(9;22) that had transformed to an AML. A total of 164 de 
novo adult AML samples remained for further analysis. 
 
Abbreviations: AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; MDS, 
myelodysplastic syndrome; MPN, myeloproliferative neoplasm; CE, capillary electrophoresis; FBC, 
full blood count; FISH, fluorescent in situ hybridisation; FLT3-ITD,  internal tandem duplication of 
the FMS related tyrosine kinase 3 (FLT3) gene;  NPM1, nucleophosmin 1 gene; Pos, positive; Neg, 
negative; Mut, mutation 
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3.2 DNA PURITY 
Prior to the assessment for NPM1 and FLT3-ITD, the DNA quality with regards to 
protein contamination was assessed. Of the 152 samples which were assessed for 
DNA quality 38% (58) were found to have a 260/280 ratio between 1.8-2.0 which 
is considered to be pure DNA.  A ratio below 1.8 indicates protein contamination 
while a value <1.5 may still be considered to be acceptable in certain 
circumstances. A total of 27.7%  (42) samples were found to have a 260/280 ratio 
of <1.5. If more sample was available on these poor quality samples it was re-
extracted, if not the original sample was still used. 
 
3.3 DNA INTEGRITY 
The DNA integrity of 32 random samples from the study cohort was assessed by 
means of confirming the presence of the glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) housekeeping gene.  In Figure 3.2 a 2% agarose gel 
(Bioline Ltd, London, UK) using 1xTBE buffer (Merk, Darmstadt, Germany) 
illustrates representative samples with adequate DNA integrity. A DNA ladder was 
used (O’GeneRuler™ 50bp DNA ladder ready-to-use) to confirm the expected 
molecular weight for the GAPDH product.  
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Figure 3.2 PCR for GAPDH. 
The PCR products were separated on 2% agarose gel using 1x TBE buffer to confirm DNA integrity 
Samples T1-T12 are all cases diagnosed with de novo AML from which DNA was extracted for 
NPM1 and FLT3-ITD assessment. 
 
Abbreviation: GAPDH, Housekeeping gene found in human cells.  
 
 
Initially PCR products for NPM1 and FLT3 were analysed by gel electrophoresis.  
Figure 3.2 demonstrates results from 2% agarose gels (Bioline Ltd, London, UK) 
using 1x TBE buffer to assess the individual NPM1 and FLT3 PCR reactions. A 
2% agarose gel (Bioline Ltd, London, UK) was used for the electrophoresis of the 
PCR products. This was able to discriminate the FLT3 band region from the NPM1 
band region by assessing for the expected molecular weights (O’GeneRuler™ 
50bp DNA ladder ready-to-use).  Results from samples N5-N8, Q1, Q2 F5, F8 and 
T26-T28 are displayed in Figure 3.3. The gel assessments were done as part of 
the initial troubleshooting to confirm that products were being obtained in the 
expected regions before further analysis by means of capillary electrophoresis 
took place.  
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Figure 3.3 Agarose gels demonstrating gene products for FLT3 and NPM1. 
(A) FLT3 ~330bp (B) NPM1 ~170bp. Both genes have different molecular weights and have been 
assessed relative to a 50bp DNA ladder. All the cases (N5-N8, Q1-Q2, F5, F8 and T26-T28) were de 
novo AML cases. Sample N7 and T28 did not yield a product for NPM1.  
 
Abbreviations: FLT3, FMS-like tyrosine kinase receptor gene; NPM1, nucleophosmin1 gene;  +ctl, 
positive control. 
 
3.4 PCR, INITIAL GEL AND CAPILLARY ELECTROPHORESIS 
ASSESSMENTS 
The PCR master mix and conditions for performing the reactions were optimised. 
Initially the AmpliTaq Gold® DNA Polymerase (Applied Biosystems, Inc., Foster 
City, CA) volume was increased in order to obtain a product. Another of the 
optimisation steps was to determine which polymerase enzymes were the most 
suitable for use in this project. The results (Figure 3.4) suggest that AmpliTaq 
Gold® DNA Polymerase (Applied Biosystems, Inc., Foster City, CA) was better 
suited compared to AmpliTaq ® DNA Polymerase (Applied Biosystems, Inc., 
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Foster City, CA) for this particular PCR reaction.   A 2% agarose gel (Bioline Ltd, 
London, UK) was used to electrophorese the same samples, but different DNA 
polymerase enzymes were used. All the other variables e.g. the thermal cycler 
used, the buffer, the cycling temperatures and the cycling times were kept 
constant. 
 
  
Figure 3.4 Comparison of commercially available DNA polymerases. 
AmpliTaq Gold® and AmpliTaq® DNA Polymerase. The PCR product being assessed is NPM1. The 
PCR conditions were the same for both DNA polymerases. AmpliTaq Gold appears to have a 
better PCR product yield with 5 of the 6 expected products expressed. A 2% agarose gel was used. 
 
All the samples (N1-N4) were extracted from cases diagnosed with AML. 
Abbreviations: NPM1, nucleophosmin 1 gene; N1e, N1 re-extracted. 
 
Other changes made in order to optimise the results included increasing the 
number of cycles from 35 to 45, increasing the denaturing melting temperature 
from 10min to 15min and increasing both the annealing time and the extension 
time from 40 sec respectively to 60 sec each. Initially both 2% and 2.5% agarose 
gels were used before it was determined that 2% gels yielded a clearer PCR 
product band. All of these optimisation steps were part of an initial attempt to 
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obtain PCR product on the gel and then to improve the brightness of the bands 
present. 
PCR product for capillary electrophoresis was assessed as neat, 1:10 and 1:30 
dilutions. The 1:30 dilution resulted in the highest peak intensities.  
 
3.5 CONTROLS 
The controls consisted of 18 EDTA blood samples and 4 bone marrow aspirate 
slides, stored, post-analysis of the requested tests. The blood and slides used to 
assess for FLT3 and NPM1 by means of capillary electrophoresis. The samples 
were obtained from non-oncology wards and clinics and there was no suspicion or 
evidence of an acute leukaemia. As they were all expected to be negative for both 
mutations, these samples were used as negative controls to determine the 
position and intensity level of background noise. Of the 18 blood samples and the 
4 bone marrow aspirate slides all were found to be NPM1-wt (as expected) with 
almost no background noise. There were no peaks found in the NPM1-mut region 
(i.e. 4bp larger than NPM1-wt). All the samples were also all FLT3-wt and 
accordingly had a peak in the expected region of 330bp. There was also a peak in 
the region of 333bp in 11 of these samples (peripheral blood samples). This was 
also relatively common in the study samples and was excluded as background 
noise. Furthermore, 4 of the samples had peaks in the region of 338bp (peripheral 
blood samples); this was also commonly noted in the study samples and was also 
considered to be part of the background noise. Figure 3.5 demonstrates 
electropherogram images with low background noise intensity seen in C2 and 
absent background noise in C6. All samples have noise prior to the peaks of 
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interest. Table 3.1 demonstrates all the control samples together with the NPM1-
wt and FLT3-wt peak position and intensity as recorded in each control. This 
includes the 18 blood samples (C1-C18) and the 4 bone marrow aspirate slide 
samples (C19-C22). 
 
A. 
 
 
B. 
 
Figure3.5 Examples of electropherograms produced in control samples. 
Sample C2 (A) has low peak intensities of background noise as indicated by the arrows. Sample C6 
(B) has no background noise recorded. 
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Table 3.1 NPM1-wt and FLT3-wt size and intensity in control samples. 
Any background noise peaks was also assessed in these 18 controls. 
 
SAMPLE NPM1-wt       SIZE 
NPM1-wt 
INTENSITY 
FLT3-wt        
SIZE 
FLT3-wt 
INTENSITY 
C1 
169.34                         
171.04 
8247                             
8741 
329.65                         
331.11                      
333.4 
9143                              
9156                          
58 
C2 
169.1                              
170.9                            
187.36 
7740                             
7396                                 
54 
329.76                                       
333.61                   
338.36                     
355.48 
8049                                                 
470                                
66                                    
140 
C3 
169.27                       
170.87 
8295                      
8469 
330.13                                             
333.48 
8241                                                
555 
C4 
169.41                     
171.0 
8213                              
8744 
330.32                         
333.64 
8989                       
326 
C5 
169.27                      
170.97 
8277                            
8377 
330.94                       
333.64                                            
9036                                
120                                                           
C6 
169.31                            
170.9 
8050                            
8507 
329.62                      
330.74 
8073                             
8644 
C7 170.91 8963 330.84 9146 
C8 
169.43                          
171.01 
8646                             
8590 331.19 4839 
C9 
169.22                     
170.07                    
7681                      
4473                           
329.62                                           
333.44 
8617                                               
529 
C10 
170.1                                              
187.95 
7669                                                             
64 
329.59                                           
333.53 
7590                                              
704 
C11 
170.08                      
171.88 
7789                             
8329 
329.72                                          
333.44 
8839
436 
C12 
170.23 7920 
 
330.42                                             
338.36 
9023                                                
50 
C13 169.9 8758 330.94 10240 
C14 
169.4 7756 331.07                        
333.49                       
337.21 
10173                                
50                                     
241 
C15 169.28 8485 331.1 2852 
C16 169.43 8493 330.94 10240 
C17 169.36 7366 331.27 1927 
 
C18 
170.98 9082 330.96              
333.56                       
337.34 
10365                               
83                                     
66 
C19 169.95 23244 329.82 2625 
C20 169.92 10360 329.16 34 
C21 169.87 15134 329.81 69 
C22 169.93 227 329.86 268 
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Abbreviations: NPM1-wt, nucleophosmin 1 gene wild type; FLT3-wt, FMS-like tyrosine kinase 
receptor gene wild type. 
 
3.6   SEQUENCING RESULTS 
In order to attempt to validate the NPM1 and FLT3-ITD mutation results, 3 of the 
FLT3-ITD mutated and 2 NPM1 mutated samples (on capillary electrophoresis) 
were amplified by means of standard procedures with the FLT3 primer pairs and 
NPM1 primer pairs described. The PCR products were purified by the standard 
methods and were sequenced directly using FLT3-reverse (FLT3-R) and NPM1-
forward (NPM1-F) primers. These primers were used as they were not fluoro-
labelled. In total of 2 of the FLT3-ITD positive samples and 1 of the NPM1 
mutation positive samples were sequenced by Inqaba Biotec™ while the other 1 
FLT3-ITD positive and 1 NPM1 mutation positive sample were sequenced by our 
laboratory (NHLS). Samples sequenced to assess for FLT3-ITD mutations were 
aligned to the Gene Bank accession number NG_00706 and a sequence trace 
was obtained for each (Figure 3.6). Samples sequenced to assess for an NPM1 
mutation were aligned to the accession number NM_002520. Unfortunately, 
although sequencing obtained results, only the wild type was amplified and the 
mutants were not identified. 
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Figure 3.6 DNA sequence analysis of Sample N44. 
The FLT3-R PCR primer was used as a sequencing primer. No internal tandem duplications were 
identified in this section or any other.  
 
Abbreviations: FLT3, FMS related tyrosine kinase 3; R, reverse. 
 
3.7 NPM1 CYTOPLASMIC STAINING 
FLEX Monoclonal Mouse Anti-Human Nucleophosmin, Clone 376, (Dako, 
Denmark, A/S) was used to assess for cytoplasmic NPM1 positivity. The presence 
of cytoplasmic NPM1 is known to concur, in most cases, with the presence of an 
NPM1 mutation (Falini et al., 2006). A total of 32 samples were assessed. These 
32 samples were chosen as they were found to have corresponding, adequate 
quality, stored trephine biopsy samples which could be used for staining. Of these, 
18 were NPM1-mut positive on molecular testing and 14 were NPM1-wt. These 
samples were assessed by 2 pathologists blinded to the molecular results. 
Pathologist 1 had correctly assessed the cytoplasmic or nuclear positivity of NPM1 
in 59% (19/32) and pathologist 2 in 53% (17/32) of samples. The mutant peak 
intensity did not appear to affect the ability to determine cytoplasmic NPM1 
positivity. These details are depicted in Table 3.2.  Figure 3.7 demonstrates the 
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presence of NPM1 nuclear and cytoplasmic staining (A and B) as seen in NPM1 
mutation positive cases as well as the presence of nuclear NPM1 staining only (C 
and D) as expected in NPM1 wild type cases. 
 
Table 3.2 Assessment of NPM1 cytochemical staining in NPM1 mut positive samples. 
The diagnosis of NPM1-mut positivity was made by means of CE and mutant peak intensity 
documented. The cytoplasmic and nuclear staining of these samples were then assessed by 2 
pathologists blinded to the CE results 
 
 
SAMPLE NPM1-mut INTENSITY On CE Pathologist 1 Pathologist 2 
R 52 8857 Cytoplasmic Cytoplasmic 
R 57 7000 Cytoplasmic Nuclear 
F19 8392 Cytoplasmic Cytoplasmic 
R 35 6077 Nuclear Nuclear 
N14 8686 Cytoplasmic Cytoplasmic 
N49 523 Cytoplasmic Cytoplasmic 
N55 8556 Cytoplasmic Nuclear 
N64 611 Cytoplasmic Cytoplasmic 
T9_R9 8862 Cytoplasmic Cytoplasmic 
R 11 109 Nuclear Cytoplasmic 
R 17 407 Cytoplasmic Cytoplasmic 
R 21 208 Cytoplasmic Nuclear 
N56 386 Cytoplasmic Nuclear 
R30_T7 243 Nuclear Cytoplasmic 
T14_F11 198 Cytoplasmic Cytoplasmic 
T8 3793 Nuclear Nuclear 
R 8 314 Cytoplasmic Cytoplasmic 
N24 209 Cytoplasmic Cytoplasmic 
 
 
Abbreviations: ; NPM1-mut, nucleophosmin 1 gene mutant; CE, capillary electrophoresis .  
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Figure 3.7 NPM1 cytoplasmic staining. 
(A) and (B) 40x magnification demonstrates NPM1 cytoplasmic positivity while (C) and (D) 40x 
magnification demonstrates NPM1 cytoplasmic negativity and nuclear positivity. 
Cytoplasmic positivity is in keeping with NPM1-mut positivity and cytoplasmic negativity with 
NPM1-wt on molecular testing.  The arrows indicate individual cells with cytoplasmic NPM1 
positivity in A and B and nuclear positivity in C and D respectively. The insets are enlargements of 
the stained tissue blocks in order to see the individual cells more clearly. 
 
Nikon ECLIPSE E400 microscope (Nikon, Tokyo, Japan) Altra 20 soft imaging system Olympic digital 
camera (Olympic, Hamburg, Germany) 
 
3.8 CAPILLARY ELECTROPHORESIS ASSAY 
Utilising capillary electrophoresis, NPM1-wt displayed consistent bands at 
approximately 170bp and NPM1-mut bands were displayed at approximately 
174bp (Figure 3.8A). FLT3-wt was displayed at approximately 330bp while the 
FLT3-ITD varied in length from 9bp to 163bp (Figure 3.8B) as expected by the 
predicted size that the amplification primers spanned.  
A. 
C. D. 
B. 
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Figure 3.8 Capillary electrophoresis for NPM1 and FLT3. 
(A) NPM1-mut and NPM1-wt and (B) FLT3-ITD and FLT3-wt sizes. All of the 164 samples analysed 
by capillary electrophoresis were included. Both the NPM1 and FLT3-ITD mutations are 
significantly different (P<0.05) in size compared to their respective gene wild type. 
 
Abbreviations: bp, base pairs; NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, 
nucleophosmin 1 gene wild type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal 
tandem duplication; FLT3-wt, FMS-like tyrosine kinase receptor gene wild type. 
 
Reproducibility of the assay was partially assessed by means of retrospective 
analysis of samples. A limited set of randomly selected samples (15) were re-
assessed using the same methods as previously described. Of these samples 6 
were controls and the other 11 samples were positive for either FLT3-ITD or 
NPM1-mut or both. All of these samples confirmed both the presence of the wild 
type and the mutants previously described in each sample. All of the wild type and 
mutant peaks reported appeared to be of a similar bp size to those reported on 
initial electrophoresis.   
Figure 3.9 demonstrates NPM1 and FLT3 gene wild type on capillary 
electrophoresis, while Figures 3.10 and 3.11 demonstrates NPM1 and FLT3-ITD 
mutations respectively.  Sample R63 and sample R38 were both positive for an 
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NPM1-mut as well as FLT3-ITD and were thus used as examples. Both samples 
had more than one FLT3-ITD present, but only the mutant with the highest peak 
intensity was labelled.  The NPM1-wt fragment lengths can range from 169 to 
171bp with what appears to be the presence of a fragment length polymorphism.  
 
 
Figure 3.9 Capillary electrophoresis pattern of NPM1 and FLT3 wild type peaks. 
Demonstration of (A) NPM1 and (B) FLT3 wild type peaks. Sample R64 (A) demonstrates an NPM1 
wild type ‘single peak’ at 170.30bp with a peak intensity of 9109, while Sample T18 (B) 
demonstrates a FLT3 gene wild type peak at 330.1 bp with a peak intensity of 8223. 
 
Abbreviations: bp, base pairs; NPM1-wt, nucleophosmin 1 gene wild type; FLT3-wt, FMS-like 
tyrosine kinase receptor gene wild type 
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Figure 3.10 Capillary electrophoresis patterns showing heterozygosity for NPM1-wt and mutant 
peaks. 
Sample (A)R63 and (B)R38 are heterozygous for NPM1. The bp position and peak intensities are 
displayed for both the NPM1-mut and NPM1-wt peaks. 
 
Abbreviations: bp, base pairs; NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, 
nucleophosmin 1 gene wild type. 
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Figure 3.11 Capillary electrophoresis patterns showing heterozygosity for FLT3-wt and FLT3-ITD 
peaks. 
Sample (A) R63 and (B)R38 are positive for FLT3-wt and FLT3-ITD. The bp position and peak 
intensities are displayed as part of the labelling above.                                                                                       
 
Abbreviations: bp, base pairs; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem 
duplication; FLT3-wt, FMS-like tyrosine kinase receptor gene wild type. 
 
More detailed information of each sample which was found to be either NPM1 
mutation positive, FLT3-ITD mutation positive or which was found to have dual 
positivity can be found in Appendix 5.2. Figure 3.12 demonstrates a common 
phenomenon where two NPM1 wild type fragments, with a 1bp difference was 
noted. 
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Figure 3.12 NPM1-wt ‘double peak’ at 169bp and 170.78 bp. 
This suggests the presence of an intronic fragment length polymorphism. 
 
Abbreviations: bp, base pairs; NPM1-wt, nucleophosmin 1 gene wild type. 
 
3.9 CRITERIA FOR NPM1 AND FLT3-ITD MUTATION POSITIVITY 
All of the cases in our cohort found to have a peak corresponding to the expected 
mutation peak position were included for analysis. This included those with a low 
level of mutation peak fluorescent intensity (arbitrary units). As part of this study a 
more comprehensive analysis of all the NPM1-mut and FLT3-ITD positive cases 
was done to try and determine a clear limit of “noise to signal ratio” and 
consequently confirm the true presence of these mutations with a low level peak 
fluorescent intensity. In order to establish the appropriate value to consider as a 
“cut-off” between positive and indeterminate, all the fluorescent intensities of the 
respective mutant peaks (NPM1 or FLT3) were determined. Figure 3.13 
demonstrates all of these mutation positive cases ranked by fluorescent intensity 
for NPM1-mut and FLT3-ITD respectively.  This area of research is part of ongoing 
work in the laboratory. 
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Figure 3.13 Determination of “cut-offs” for indeterminate peak intensities. 
(A) Analysis of NPM1-mut peak intensity. A peak intensity of >1000 may be an appropriate value 
at which to consider the sample as mutation positive. (B) Analysis of FLT3-ITD peak intensity. A 
peak intensity of >500 may be an appropriate value at which to consider the sample as mutation 
positive. 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; FLT3-ITD, FMS-like tyrosine kinase 
receptor gene internal tandem duplication. 
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The use of a “cut-off” value of >100 was also considered after correspondence 
with two authors who had recently published information in this regard (Szankasi 
et al., 2008, Wertheim and Bagg, 2008, Buban et al., 2011). The first 
correspondent includes all patient samples with a mutation peak of any intensity 
into the positive group including those with an intensity of <100. The second 
correspondent uses a peak intensity of >100 as a determinant to call a result 
positive.  For illustrative purposes only, if the criterion, of a peak intensity of >100, 
was used, a slight variation in the frequency of both NPM1-mut and FLT3-ITD was 
found, with the frequency for both decreasing (Figure3.14). All peak intensity 
levels, including those with values of <100 were used in the analysis of our study 
cohort.  
Also, when analysing the control samples any background noise was recorded for 
both intensity and position. This noise did not peak at intensities >70 in the NPM1 
assay and did not occur in the expected size range for this mutation. The 
background noise did not peak at intensities >150 in the FLT3 assay. 
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Figure 3.14 NPM1-mut and FLT3-ITD using peak intensities of >100 as a “cut-off”. 
Assessment of (A) NPM1-mut and (B) FLT3-ITD in AML cases. Samples with a peak intensity of 
<100 were considered to be within an indeterminate range. 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; FLT3-wt, FMS-
like tyrosine kinase receptor gene wild type. 
 
3.10  DILUTIONAL STUDY 
It has been reported that PCR and capillary electrophoresis has a diagnostic 
sensitivity of 100% and an analytical sensitivity of 5%. This means that all the 
known NPM1 mutations can be detected provided that the leukaemic cells 
represent 5% of the cells present.  
Sample N55 which was found to be NPM1-mut positive with a sample blast count 
of approximately 85% blasts was used in a serial dilution study to attempt to 
determine the assay sensitivity. A serial dilution using Sample N55 as the mutant 
DNA and a control sample as the wild type DNA was assessed by means of 
capillary electrophoresis. The dilution series included a 1:64 dilution which 
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remained positive for the mutation. This finding suggested that the assay was 
indeed sensitive for the detection of the NPM1 mutation. 
Sample T2 which was found to be FLT3-ITD positive with a sample blast count of 
approximately 96% blasts was used in a serial dilution study to attempt to 
determine the assay sensitivity. A serial dilution using Sample T2 as the mutant 
DNA and a control sample as the wild type DNA was assessed by means of 
capillary electrophoresis. The dilution series included a 1:64 dilution which 
remained postitive for the mutation. This finding suggested that the assay was 
indeed sensitive for the detection of the NPM1 mutation. 
A sample that was confirmed NPM1 mutation positive and FLT3-ITD positive with 
a blast count of 30% was serially diluted with distilled H2O and assessed by means 
of capillary electrophoresis.  The sample was electrophoresed neat up to and 
including 1:128 dilution. Both the wild type and mutant remained  present in all the 
dilutions with a minimal drop in peak values with increased dilution. This suggests 
that the capillary electrophoresis method of detection is robust. 
 
3.11 FLT3 MUTANT LEVEL 
The FLT3 mutant level was determined to further assist in prognostication. The 
cohort of FLT3-ITD positive samples, seen in Table 3.3 and Figure 3.15 was 
divided into the three risk group categories as suggested by Gale et al. (Gale et 
al., 2008) which found the three groups to have different outcomes. The three risk 
groups were determined by assessing the relative mutant level. This was 
calculated by using the area under the mutant peak curve and expressing it as a 
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percentage of the total FLT3 (Further described in Appendix 5.1).  The risk 
categories are low risk (<25% mutant), intermediate risk (25% to 50% mutant) and 
high risk (>50% mutant).  This risk assessment appears to affect both RR and OS 
with those with a high total mutant level doing significantly worse than those in the 
intermediate group. Those in the low risk group had a significantly worse RR 
compared to those with FLT3-wt (Gale et al., 2008).    
 
Table 3.3 Analysis of the FLT3-ITD/ FLT3-wt ratio. 
The percentage FLT3-ITD mutant in the sample impacts on clinical outcome.  
 
 
Low Risk         
(<25%) 
Intermediate Risk  
(25-50%) 
High Risk              
(>50%) 
Number of Patients 
(%) 
15 (50%) 12(40%) 3(10%) 
Median Mutant Level 6% 40% 64% 
Abbreviations: FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; 
FLT3-wt, FMS-like tyrosine kinase receptor gene wild type. 
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Figure 3.15 Percentage FLT3-ITD relative to total FLT3 in that sample. 
These have then been subdivided into three different risk categories.  
 
Abbreviations: FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; 
FLT3, FMS-like tyrosine kinase receptor gene. 
 
3.12 PATIENT CHARACTERISTICS 
Of the 164 cases analysed 37% (61/164) were found to have one of the specified 
mutations i.e. NPM1-mut, FLT3-ITD or both.   
In total, 21% (34/164) were found to have FLT3-ITD and 26% (42/164) were 
NPM1-mut positive. A total of 9% (15/164) of the cases were found to have both 
these mutations occurring in combination (Figure 3.16). FLT3-ITD mutations were 
found in 36% (15/42) NPM1-mut cases, which is statistically significantly higher 
when compared with 16% (19/122) of the NPM1-wt cases (P<0.04). This data 
confirms that NPM1-mut and FLT3-ITD characterise major, partially overlapping 
subgroups in AML. For this reason all further analyses were performed according 
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to 4 groups. These groups consisted of the two mutations in combination, each 
individually and a wild type group which was negative for both these mutations. 
 
Figure 3.16 Frequency of NPM1 and FLT3-ITD mutations. 
Assessment of the frequency of NPM1 and FLT3-ITD mutations in relation to each other as well as 
those patients diagnosed with AML but negative for these specific gene mutations. 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; FLT3-wt, FMS-
like tyrosine kinase receptor gene wild type. 
 
 
This cohort of 164 cases had a minor female to male predominance with 51% 
(84/164) female and 49% (80/164) male patients.  It has been reported that NPM1-
mut tends to occur with a higher frequency in female patients with a male: female 
ratio of 1:1.5 (Thiede et al., 2006). In this patient population, 60% (25/42) of the 
patients who were NPM1-mut positive were also female (i.e. male to female ratio 
of 1:1.5) (Figure 3.17). 
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Figure 3.17 Gender relative to the various mutation combinations. 
 
No statistical difference was found between the different mutation groups. 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; FLT3-wt, FMS-
like tyrosine kinase receptor gene wild type; no; number. 
 
The median age of diagnosis of AML was found to be 40 years in this cohort of 
cases.  Within all the patient groups the age range was found to be similar with the 
exception of those who were NPM1-mut only (NPM1-mut/FLT3-wt) and those who 
had both mutations (NPM1-mut/FLT3-ITD).  This data set showed that those who 
were NPM1-mut positive were younger than expected with a median age of 30 
years, while those who were mutation positive for both (NPM1-mut/FLT3-ITD) had 
a median age of 60 years (P>0.05) (Figure 3.18).  
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Figure 3.18 Age relative to NPM1 and FLT3-ITD mutation status. 
  
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; FLT3-wt, FMS-
like tyrosine kinase receptor gene wild type. 
 
Of the NPM1-mut only (NPM1-mut/FLT3-wt) cases, with a FAB diagnosis 
documented, 55% (11/20) were either FAB M4 or M5. In those patients who were 
NPM1-wt 34% (26/76) patients were classified as FAB M4 or M5. Furthermore, 
38% (6/16) of the samples that were FLT3-ITD only and had been classified by 
means of FAB were found to be FAB M4 or M5. FAB M5 was found to be the most 
common classification group, in both the NPM1-mut only (NPM1-mut/FLT3-wt) 
and the FLT3-ITD only (NPM1-wt/FLT3-ITD) group. In the group negative for both 
(NPM1-mut/FLT3-ITD) these mutations, FAB M2 and M3 were the most common 
FAB classification.  Although not statistically significant these trends concur with 
 70 
 
those reported in the literature (Swerdlow et al., 2008). Patient characteristics for 
age, gender and FAB classification are summarised in Table 3.4. 
The anaemia and thrombocytopenia at diagnosis as previously described 
(Swerdlow et al., 2008)  was confirmed in patients who were NPM1-mut positive. A 
leucocytosis and high blast count was also confirmed (Swerdlow et al., 2008) but 
was not found to be statistically significantly higher than in the other sub-groups 
investigated (P>0.05).  
The expected leucocytosis and high blast count in those with FLT3-ITD positivity 
was also found to be present in this cohort of FLT3-ITD positive samples (Thiede 
et al., 2006, Suzuki et al., 2007). These clinical characteristics are summarized in 
Table 3.5. Compared to AML patients without NPM1 or FLT3-ITD mutations 
patients showing both of these mutations simultaneously (NPM1-mut/FLT3-ITD) 
had statistically significantly higher median Hb (7.4 g/dl versus 9.5 g/dl; P< 0.05). 
Furthermore, patients with both mutations (NPM1-mut/FLT3-ITD) were also found 
to have a statistically significantly higher median Hb (9.5 g/dl versus 6.8 g/dl; P< 
0.03) when compared to those with NPM1-mut only (NPM1-mut/FLT3-wt) as well 
as when compared to those with FLT3-ITD only (NPM1-wt/FLT3-ITD) (9.5 g/dl 
versus 6.9 g/dl; P< 0.04). 
Patients with the NPM1-mut only (NPM1-mut/FLT3-wt) were found to have a 
statistically significantly reduced median platelet count (24.5 x109/l versus 53.5 
x109/l; P< 0.05) when compared to those with only an FLT3-ITD (NPM1-wt/FLT3-
ITD) and this appears to be a novel finding. 
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Table 3.4 Assessment of age, gender and AML FAB classification. 
This is assessed relative to the presence of NPM1 and FLT3-ITD mutations. 
 
 
 
CHARACTERISITCS 
FLT3-ITD negative FLT3-ITD positive 
NPM1-mut 
n=27 
NPM1-wt 
n=103 
NPM1-mut 
n=15 
NPM1-wt 
n=19 
Gender: n=27 n=103 n=15 n=19 
     Male (%) 11 (40%) 53 (52%) 6 (40%) 10 (53%) 
Age (years): n=26 n=101 n=15 n=19 
     Median 30 41 60 36 
     Range 18-79 17-80 19-67 17-80 
FAB: n=27 n=103 n=15 n=19 
      MO (%) 1 (4%) 6 (6%) 0 (0%) 1 (5%) 
      M1 (%) 0 (0%) 0 (0%) 3 (20%) 0 (0%) 
      M2 (%) 6 (22%) 20 (19%) 2 (13%) 4 (21%) 
      M3 (%) 2 (7%) 21 (20%) 0 (0%) 3 (16%) 
      M4 (%) 3 (11%) 8 (8%) 1 (7%) 1 (5%) 
      M5 (%) 8 (30%) 18 (17%) 4 (27%) 5 (26%) 
      M6 (%) 0(0%) 1 (1%) 0 (0%) 0 (0%) 
      M7 (%) 0 (0%) 2 (2%) 0 (0%) 2 (11%) 
NO RESULT 
For FAB (%) 
7 (25%) 27 (26%) 5 (33%) 3 (16%) 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; FLT3-wt, FMS-
like tyrosine kinase receptor gene wild type; FAB, French American British 
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The WCC count of those patients who were only FLT3-ITD positive (NPM1-
wt/FLT3-ITD) demonstrated a marked leucocytosis with a median WCC of 101 
x109/l. This was found to be statistically significantly increased when compared to 
the median WCC of those with an NPM1-mut only (NPM1-mut/FLT3-wt) (101 
x109/l versus 15.9 x109/l; P< 0.03) and those with neither an NPM1-mut nor FLT3-
ITD (101 x109/l versus 12.2 x109/l; P< 0.02).  
 
Table 3.5 Clinical characteristics at diagnosis. 
These have been subdivided according to the presence of NPM1 and FLT3-ITD mutations. 
 
 
CHARACTERISITCS 
FLT3-wt, n=130 FLT3-ITD, n=34 
NPM1-mut 
n=27 
NPM1-wt 
n=103 
NPM1-mut 
n=15 
NPM1-wt 
n=19 
Median Hb level, 
g/dl (range) 
6.8              
(2.5-12) 
7.4                
(2.5-12) 
9.5               
(7.0-13.6) 
6.9              
(3.0-13.1) 
Missing 12 32 3 3 
Median Plt count, 
x109/L (range) 24.5 (9-151) 32 (6-1149) 43 (9-157) 53.5 (11-398) 
Missing 11 32 4 3 
Median WCC, x109/l 
(range) 
15.9            
(1.1-78.4) 
12.15              
(0.69-459.4) 
10.23            
(2.2-376) 
101             
(1.6-582) 
Missing 11 32 3 3 
Median blasts at Dx, 
% (range) 52 (6-85) 57.5 (8-95) 72.5 (14-95) 65.0 (13-96) 
Missing 2 1 1 0 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutation; NPM1-wt, nucleophosmin 1 gene 
wild type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; FLT3-wt, 
FMS-like tyrosine kinase receptor gene wild type; Hb, haemoglobin; Plt, platelet; WCC, white cell 
count; Dx, diagnosis. 
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3.13 NPM1 AND FLT3-ITD MUTATIONS AND IMMUNOPHENOTYPING 
All the immunophenotypic markers commonly used as part of routine flow 
cytometric assessment were investigated to determine if there was any significant 
association between marker expression and NPM1 and FLT3-ITD mutational 
status.  
More specifically CD14, CD11b and human leucocyte antigen DR (HLA-DR) were 
statistically significantly increased in all the samples which were NPM1-mut 
positive (FLT3-ITD or FLT3-wt) (P<0.05).  When assessing those samples which 
had both mutations (NPM1-mut/FLT3-ITD), it was noted that CD56 was negative 
in 100% (8/8) of the samples compared to the wild type samples of which 35% 
(22/63) of the samples assessed were CD56 positive (P<0.05). 
When assessing CD34 expression and NPM1-mut, 48.7% (19/39)) of the cases 
that were NPM1-mut positive were also reported to be CD34 positive. The CD34 
analysis of two representative cases are shown in Figure 3.19. The CD34 dot plots  
demonstrate a CD34 positive case (A) and another with virtual absence of CD34, 
that was considered negative  (B).  
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Figure 3.19 Dot plot of CD34 (FITC) expression on the X axis vs. CD7 (PE) on the Y axis in NPM1 
mutant cases. 
(A) CD34 positive population of cells is represented by the purple events and (B) CD34 negative 
population is represented by the red events. The purple population represents mature T-cells. 
These assessments were made in conjunction with an isotypic negative control (not in this figure). 
 
 
Those samples that were found to be NPM1-wt were statistically significantly more 
likely to be CD34 positive than NPM1-mut cases as shown in Figure 3.20 
(P<0.001). When assessing NPM1-mut only (NPM1-mut/FLT3-wt), 44% (11/25) of 
the samples were found to be CD34 negative. This is a higher percentage than 
described in the international literature.  
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Figure 3.20 CD34 expression in NPM1-mut and NPM1-wt cases. 
NPM1-wt cases are statistically significantly more likely to be CD34 positive than NPM1-mut cases 
(P<0.001). 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type. 
 
As expected CD 13, a myeloid marker,  was positive in 90% (35/38) NPM1-mut 
positive samples assessed. A similar result with another myeloid marker, CD33, 
was observed with 97% (38/39) NPM1-mut positive samples assessed. 
 
3.14 NPM1 AND FLT3-ITD MUTATIONS AND CYTOGENETIC EVALUATION 
Of the 42 patients who were diagnosed as  NPM1-mut positive 29% (12/42) had 
an abnormal cytogenetic result and 19% (8/42) were found to be cytogenetically 
normal. The remaining 52% (22/42) had no cytogenetic result available (i.e.no 
fluorescent in situ hybridisation (FISH) or karyotype results). Figure 3.21 gives an 
 76 
 
indication of the frequency of cytogenetic abnormalities seen in NPM1 mutation 
positive cases. 
 
 
Figure 3.21 NPM1-mut cases and cytogenetic results. 
 
(A) NPM1-mut positive cases and the cytogenetic findings for the group as a whole and (B) closer 
assessment of the NPM1-mut positive cases that have a cytogenetic result recorded.   
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant. 
Those samples that were NPM1-mut positive with an abnormal karyotype are 
presented in Table 3.6. Both the mutant position and peak intensity have been 
included. The intensity of NPM1-mut peaks was determined in relation to the 
 77 
 
presence of the above mentioned genetic mutations. The majority of the samples 
and in particular those with a recurrent chromosomal translocation as classified by 
WHO 2008, have mutation peak intensities of <550. 
 
Table 3.6 Confirmed abnormal karyotype in NPM1-mut positive samples. 
The NPM1-mut position and intensity has also been included. 
 
SAMPLE CYTOGENETICS MUT POSITION MUT INTENSITY 
R8 Inv(16) 173.76 314 
R30 5% cells positive for inv16 173.48 243 
N49 t(15;17) 173.58                                         174.42 
523                                               
400 
R11 +11 174.22 109 
R51 del(13)(q14) 174.27 7223 
N93_N23 t(3;5)(q25;q34) 173.24 294 
R35 inv(9) 174.61 6077 
R14_F18 del(7)(q?33),t(8;21)(q22;q22) 173.61 61 
N24 t(8;21) 173.67 209 
R36_F23 t(8;21) 173.32 161 
R3 t(15;17) 173.56 165 
R53 11q23 173.7 290 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; inv, inversion; t, translocation; del, 
deletion. 
  
FLT3-ITD mutations were found in 36% (15/42) of NPM1-mut cases compared 
with 16% (19/122) of the NPM1-wt cases (P<0.04). Figure 3.22 illustrates how 
FLT3-ITD preferentially targets those patients who are NPM1-mut positive. This 
association has also been reported by others (Thiede et al., 2006).  
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Figure 3.22 FLT3-ITD preferentially target NPM1-mut positive samples. 
44% (15/34) of the FLT3-ITD positive samples are also NPM1-mut positive.  
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; FLT3-wt, FMS-
like tyrosine kinase receptor gene wild type. 
 
 
Of the FLT3-ITD cases, 58% (11/19) had cytogenetic abnormalities detected while 
42% (8/19) were found to be CN. Those with confirmed abnormal FISH analysis 
results were included in the cytogenetically abnormal group even though not all of 
them had a karyotype result available. The other 15 either had failed cytogenetic 
results, or no genetic analysis was requested at all. Of those who were FLT3-ITD 
only (NPM1-wt/FLT3-ITD), 13 had a karyotype result available of which 38% (5/13) 
had a normal karyotype (P>0.05). Only 3 of the 34 samples that were FLT-ITD 
positive carried a t(15;17) (P>0.05). All FLT3-ITD positive cases with abnormal 
cytogenetics are summarised in Table 3.7. Some of these abnormal karyotypes 
are commonly associated with FLT3-ITD, while others are less frequently 
associated and others very rarely associated. The mutation peak position and 
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intensity is included in order to better assess whether some of these FLT3-ITD 
mutations and rare cytogenetic associations may form part of the described 
indeterminate range. A summary of both the FLT3-ITD and NPM1-mut results 
relative to the karyotype findings is represented in Table 3.8. 
 
Table 3.7 Confirmed abnormal karyotype in FLT3-ITD positive samples. 
The FLT3-ITD mutation position and intensity has also been included. 
 
SAMPLE CYTOGENETICS MUT POSITION 
MUT:WT  
RATIO 
R27 t(15;17) 371.13 0.75 
T2 t(15;17) 371.22 0.15 
F3 t(15;17) 344.04 352.34 0.77                                   
F6 t(8;21) 355.41 0.01 
T15/N31/T27 t(8;21) 385.0 0.04 
F4 t(8;21) 391.02 0.03 
R11 47XX,+11 360.07 0.19 
R51 del (13) 378.98                        408.85 0.39                    
F24 
46,XX,del(12)(p?13) 
[8]/45,XX,der(8;12)(q10;q10)  
[2]/46,XX [2] 
392.32                                       
415.72                       
424.43 
0.63                                                                                          
N93 46,XY,t(3;5)(q25;q34) 372.91 0.60 
N94 46,XY,t(2;17)(p?23;q25) 339.28 0.03 
 
Abbreviations: FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; t, 
translocation; del, deletion. 
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Table 3.8 Cytogenetic results relative to NPM1 and FLT3 mutations. 
The cytogenetic results (FISH and/or karyotype) were documented at diagnosis. In some of these 
cases there were no karyotype results but FISH analysis was able to confirm an abnormal result. 
Assessment for single or multiple cytogenetic abnormalities was therefore not possible in those 
cases with FISH analysis only. 
 
 
NPM1-mut/      
FLT3-wt 
FLT3-ITD/ 
NPM1-wt 
NPM1-mut/      
FLT3-ITD 
NPM1-wt/         
FLT3-wt 
Karyotype: n=14 n=13 n=6 n=69 
Normal Cytogenetics 
(%): 
5 (36%) 5(38%) 3 (50%) 13(19%) 
Abnormal 
Cytogenetics (%): 
9(64%) 8(62%) 3(50%) 56(81%) 
No. with 
Abnormalities: 
n=5 n=7 n=3 n=34 
Single Abnormality 
(%): 
4(80%) 2(29%) 3(100%) 14(41%) 
Multiple 
Abnormalities (%): 
1(20%) 
 
5(71%) 0 20(59%) 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; FLT3-wt, FMS-
like tyrosine kinase receptor gene wild type; FISH, fluorescent in situ hybridisation.  
 
3.15 LONGITUDINAL CASE STUDY ASSESSMENT 
An assessment of 10 cases, which  had samples available from different time 
periods in the course of their disease, was made. A longitudinal analysis was 
performed to determine whether these two gene mutations remain stable 
throughout the disease course. In particular, it has been reported that NPM1 
mutations are more stable than FLT3-ITD mutations and may be used for the 
detection of MRD (Falini et al., 2009). Occasionally both these mutations may be 
gained or lost at relapse (Suzuki et al., 2005). Analysis of this study cohort cases 
demonstrated no gains of either of the mutations, however, loss of NPM1-mut in a 
single sample was noted.  
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Case 1 (Samples N71 and N28): 
At diagnosis the patient was found to be NPM1-mut positive only (NPM1-
mut/FLT3-wt). At relapse a similar analysis profile was found (Table 3.9).   
 
Table 3.9 NPM1-mut positivity confirmed at diagnosis and relapse. 
 
 
Diagnosis 
Position 
Diagnosis 
Intensity 
Relapse 
Position 
Relapse  
Intensity 
NPM1-wt 170.62 8812 169.96 8446 
NPM1-
mut 174.51 8542 174.03 8484 
FLT3-wt 330.1 7320 330.34 8686 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type; FLT3-wt, FMS-like tyrosine kinase receptor gene wild type. 
 
 
Case 2 (Sample T15, N31 and T27): 
At diagnosis (T15), the patient was found to have a FLT3-ITD but was NPM1-mut 
negative (NPM1-wt/FLT3-ITD). At relapse 1 (N31) and at relapse 2 (T27) FLT3-
ITD mutation was found at the same position as at diagnosis and the NPM1-mut 
was absent (Table 3.10). 
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Table 3.10 FLT3-ITD positivity at diagnosis and at both relapses. 
 
 
Diagnosis 
Position  
Diagnosis 
Intensity   
Relapse 1 
Position 
Relapse 1 
Intensity 
Relapse 2 
Position 
Relapse 2 
Intensity  
NPM1-
wt 170.41 9440 170.77 7586 170.18 5205 
FLT3-
wt 330.0 9488 331.14 9901 329.98 9812 
FLT3-
ITD 385.28 8309 385.34 477 385.32 560 
 
Abbreviations: NPM1-wt, nucleophosmin 1 gene wild type; FLT3-ITD, FMS-like tyrosine kinase 
receptor gene internal tandem duplication; FLT3-wt, FMS-like tyrosine kinase receptor gene wild 
type. 
 
Case 3: (Sample T1 and T28): 
As seen in Table 3.11 both diagnosis and relapse samples are positive for a FLT3-
ITD found at approximately the same position. The ratio of intensity for wild type: 
mutant was much less on follow up. An NPM1-mut was found at diagnosis but was 
not present on follow up. 
 
Table 3.11 FLT3-ITD at presentation and relapse. 
The NPM1-mut present at presentation was not found at relapse. 
 
 
Diagnosis  
Position  
Diagnosis 
Intensity   
Relapse 
Position 
Relapse 
Intensity  
NPM1-wt 169.33 8018 169.96 8446 
NPM1-
mut 173.35 669 Not present 8484 
FLT3-wt 330.81 9680 330.34 8686 
FLT3-ITD 418.69 3030 417.0 211 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type; FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; FLT3-wt, FMS-
like tyrosine kinase receptor gene wild type. 
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Another  2 cases which were assessed longitudinally were found to be NPM1-mut 
and FLT3-ITD positive (NPM1-mut/FLT3-ITD) at diagnosis and at relapse. 
A further 5 longitudinal assessments of cases who were initially both NPM1-wt and 
FLT3-wt were made. At relapse both these mutations were assessed again and no 
gains of either of these mutations were found at relapse. 
The findings of those cases assessed longitudinally were as expected. Case study 
3 demonstrated a loss of the NPM1-mut; this is a less common finding with the 
presence of NPM1-mut likely to be used as a measure for minimal residual 
disease in the future (Palmisano et al., 2007). 
 
3.16 SUMMARY OF RESULTS 
A retrospective analysis was performed of samples from adult patients diagnosed 
with de novo AML at CMJAH from September 2004 until December 2009. A total 
of 164 AML patient samples were assessed for the presence of NPM1 and FLT3-
ITD mutations occurring alone and in combination.  
FLT3-ITD was found in 21% (34/164) and NPM1-mut in 26% (42/164) of these 
cases. A total of 9% (15/164) were found to have both these mutations occurring 
in combination (NPM1-mut/FLT3-ITD). FLT3-ITD was found in 36% (15/42) NPM1-
mut cases. 
Of the cases analysed, 49% (80/164) were male and 51% (84/164) female. The 
median age at diagnosis was found to be 40 years (range: 17-80 years). Of the 
male patients, 20% (16/80) were 60 years or older at diagnosis and 23% (19/84) of 
female patients were 60 years or older at diagnosis. FBC results at diagnosis were 
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assessed; with WCC results available for 115 cases and Haemoglobin (Hb) and 
platelet count results available for 114 cases. The median WCC was 12.6 x109/l 
(0.69-582), the median Hb was 7.6 g/dl (range: 2.5-13.6) and the median platelet 
count was 32.5 x109/l (range: 6-1149). Furthermore, blast count data was collected 
on 160 of these cases with a median of 58% (range: 6-97) at diagnosis. 
Of the total number of cases analysed 26% (42/164) had no FAB classification 
assigned, 21% (35/164) cases were diagnosed as FAB M5, 20% (32/164) as FAB 
AML with differentiation (AML M2) and 16%(26/164) as FAB M3.  
Assessment of cytogenetics revealed that only 46% (75/164) of cases had 
documented karyotype results available. Of these, 35% (26/75) were found to 
have a normal karyotype and the other 65% (49/75) had abnormal cytogenetics 
recorded. Of the 49 with abnormal cytogenetics 49% (24/49) had single mutations 
and 51% (25/49) presented with multiple mutations (including complex 
karyotypes). 
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Table 3.12 Summary of patient characteristics at diagnosis. 
 
Characteristics at Diagnosis % (n) 
Male, % 49% 
Female, % 51% 
Age > 60 yrs, % 21.5% 
Median age, yrs  40 yrs 
Median WCC, x109/L 12.6 
Median Hb, g/dl 7.6  
Median plt, x109/L 32.5 
FAB Classification  
No FAB % (n) 26% (42/164) 
M2 % (n) 20% (32/164) 
M3 % (n) 16% (26/164) 
M5  % (n) 21% (32/164) 
Karyotype  
Present % (n) 46% (75/164) 
Normal % (n) 35% 26/75) 
Abbreviations: Yrs, years; WCC, white cell count; Hb, haemoglobin; plt, platelet; FAB, French 
American British 
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4 DISCUSSION 
4.1 INTRODUCTION 
An assay which involves PCR amplification of genomic (g) DNA and fragment 
analysis by capillary electrophoresis has been optimised and used to assess for 
the presence of NPM1 and FLT3-ITD mutations in a de novo adult AML 
population. This is an assay which as yet, to the best of our knowledge, has not 
been routinely performed in a South African centre. It allows for the simultaneous 
detection of both NPM1 and FLT3-ITD mutations. These recently discovered key 
mutations in AML should always be assessed in conjunction with each other, not 
only initially but throughout follow up (Suzuki et al., 2007, Schlenk et al., 2008, 
Gale et al., 2008).  PCR and subsequent capillary electrophoresis is the only 
available assay to detect both mutations together and to assess for all or almost all 
NPM1 mutation subtypes. As an alternative FLT3-ITD is being detected by means 
of a PCR based gel assay and NPM1 by means of Q-PCR, PCR and sequencing 
or PCR and denaturing high performance liquid chromatography (dHPLC) 
amongst others (Wertheim and Bagg, 2008). Each of the tests has both 
advantages and disadvantages with cost and diagnostic sensitivity being the major 
determinants for their use in a routine molecular diagnostic laboratory. This newly 
instituted PCR and capillary electrophoresis testing is highly sensitive and 
relatively low cost (Wertheim and Bagg, 2008). The detection limit (analytical 
sensitivity) of this form of testing has been determined by a least two separate 
investigators and it appears that the assay can detect mutations present in 
concentrations as low as 5% (Noguera et al., 2005, Szankasi et al., 2008, 
Wertheim and Bagg, 2008). Introduction of this testing into routine use will allow 
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clinicians to gain an improved understanding of the pathobiology of each individual 
patient’s disease:  to provide a more accurate prognostic assessment and better 
stratify treatment decisions (such as when to consider bone marrow 
transplantation or more experimental drug regimens and when to include patients 
in clinical trials). This is of particular relevance in those who are assessed to have 
a normal karyotype or indeed those whose cytogenetic assessment fails. The 
robustness of this assay has been confirmed and has provided results despite, at 
times, being presented with suboptimal quality samples. Although assay specificity 
and accuracy was not determined in this research project further experimentation 
is ongoing in this regard. Furthermore, peripheral blood can be used as an 
alternative to bone marrow which makes obtaining a sample for diagnosis much 
simpler. 
 
4.2 LIMITATIONS OF THE STUDY 
The current study shows certain limitations which are acknowledged in this 
section.  
The first limitation is the number of cases included in the study. Although a total of 
164 cases were included in this study, when these are analysed in subgroups the 
patient numbers in each subgroup are small. 
The second limitation is the retrospective nature of the study together with the lack 
of clinical correlation for the cases included in this study. In particular, patients who 
are NPM1 mutation positive are often noted to have extra-medullary involvement 
and this could not be assessed. An assessment of survival in this cohort was also 
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not possible due to limited ethical clearance on this study which stipulated that 
only NHLS available patient data could be used. This limitation could be overcome 
in several ways, including seeking consent from patients at the time of diagnosis 
and this is planned for subsequent prospective studies. 
The third limitation relates to the nature of the samples obtained. Many of them 
were collected in a heparin tube which is likely to result in inhibition of the PCR 
reaction and some samples were excluded on this basis. Furthermore, samples 
(especially those of single slide extracts) yielded limited quantities of DNA thus, 
more extensive testing, such as sequencing of these samples was not possible. 
This limitation could be overcome by obtaining a sample of bone marrow in an 
EDTA tube at the time of doing the diagnostic bone marrow aspirate in a 
prospective study. The sample could be stored and DNA extracted at a later stage 
once the diagnosis of AML has been confirmed (the diagnosis is routinely made 
within less than 24 hours of the sample being collected). 
The fourth limitation was the lack of a reliable positive internal control. An NPM1 
cell line has recently been obtained, which in future work will be incorporated into 
routine diagnostics as a positive control. Alternative positive controls could be 
derived by cloning well characterised PCR reaction products of positive cases. 
 
4.3 ASSAY PROBLEMS 
4.3.1 PCR TROUBLESHOOTING 
The decision to use the fragment analysis method was partly based on the readily 
available instruments and staff expertise in PCR diagnostics and this method has 
become one of the most commonly used for the detection of NPM1 and FLT3-ITD 
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mutations, as it is the only one that can potentially provide both of these mutation 
results simultaneously (Noguera et al., 2005, Wertheim and Bagg, 2008). The 
importance of the detection of these mutations in combination has been confirmed 
in various studies as their impact on prognosis alone and in combination is 
significantly different (Mrózek et al., 2007, Haferlach et al., 2009).   
As presented in section 2.5 revisions to the master mix (Table 2.2) and PCR 
conditions were initially made before a final protocol was adopted. Individual PCR 
reactions for each of the two sets of primers (NPM1 and FLT3-ITD) were instituted 
and became the standard operating procedure for the rest of the research 
assignment. However, in the future the laboratory will attempt to optimise the 
multiplex reaction in order to reduce the cost of this assay. Different polymerase 
enzymes were tested for the PCR conditions set out for this experiment leading to 
a switch from AmliTaq® DNA Polymerase to AmpliTaq Gold® DNA Polymerase 
(Applied Biosystems, Inc. Foster City, CA). 
Possible reasons for the initial poor PCR results included poor DNA concentration 
of the samples extracted secondary to DNA degradation over time as fresh blood 
samples and BMA slides were not used. In addition, there may have been 
inhibition of the PCR reaction by a contaminant (such as heparin used in samples 
for immunophenotyping).  
The poor DNA integrity was confirmed by assessing for PCR products for GAPDH 
on gels on a random selection of the extracted patient samples. Of the 31 samples 
analysed only 48% (15/31) showed product to be present on the gel. This confirms 
that the DNA integrity of the samples available for testing plays an important role 
in the ability to produce a result.  
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Randomly chosen fresh blood samples and previously extracted BMA samples 
(rather than stored slides) were then used to assess for any differences in DNA 
integrity. The former samples were much more consistent in providing a result, in 
particular provided much higher peak intensities on capillary electrophoresis. 
Therefore, it was concluded that blood or BMA samples taken in an EDTA tube 
(rather than made into a slide and stored) should be the preferred source material 
for routine analysis going forward. 
The role of the extraction method used was also assessed. Some samples were 
extracted in duplicate using the QIAquick gel extraction kit (Qiagen, GmbH, 
Germany) as per the manufacturer’s instructions as well as the High Pure PCR 
template Preparation Kit (Roche Mannheim, Germany). The DNA concentrations 
obtained with the QIAquick gel extraction kit (Qiagen, GmbH, Germany) were 
lower than that of the High Pure PCR Kit. Thus, the decision to continue using the 
High Pure PCR template Preparation Kit in the rest of our experiments was made.  
Testing of samples after all the optimisation steps yielded good results on both the 
gels and the capillary electrophoresis.  
 
4.3.2 SAMPLE QUALITY 
Most of the samples used were assessed by means of NanoDrop® ND-1000 
(NanoDrop Technologies Wilmington, Delaware USA) in order to determine both 
DNA concentration and quality.  
Some of the samples assessed were found to be of suboptimal quality. The 
reasons for this included: age of specimen with DNA degradation likely, storage of 
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samples in suboptimal conditions and many of the samples available for extraction 
were poorly spread, single slides with little DNA present.  
Despite the above mentioned limitations of the samples available, 38% (58/152) of 
the samples assessed for DNA quality and then included in the study were 
considered to be of good quality. Those samples that were suboptimal in nature, 
for the various reasons mentioned above, and still yielded a result with high peak 
intensities on fragment analysis were included in the study sample.  The ability to 
obtain results with high peak intensities despite sub-optimal samples suggests that 
this is a robust assay. Furthermore, a total of 232 samples were collected, many of 
which were extracted and the test performed using this assay. Only 5 of the 
extracted samples did not yield a result and were therefore excluded from the 
study. The rest of the samples that underwent electrophoresis, were either 
included in the study, formed part of the longitudinal assessment of patients or 
formed part of the control group. Refer to Figure 2.1 for further details. 
Other investigators have made use of a similar approach for mutation diagnosis 
with capillary electrophoresis, but have used RNA and reverse transcriptase PCR 
(RT-PCR) instead (Noguera et al., 2005). RNA instability is, however, a major 
limiting factor to this method, especially in a retrospective study. This is particularly 
relevant in our setting where many of the samples are referred from peripheral 
centres with the interval between obtaining the specimen and analysis is often 
more than 24 hours. The clear advantages of using DNA include a stable and 
reliable starting test material and that the test can be performed on paraffin 
embedded samples as well as fresh samples.  
 A means to determine adequate DNA integrity, successful DNA extraction and 
successful PCR amplification is found in the NPM1 PCR reaction. To date all the 
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NPM1 mutant cases reported in the literature have been reported as being 
heterozygous (Swerdlow et al., 2008, Falini et al., 2007). Thus, the presence of a 
wild type peak or fragment can be considered as a positive internal control.  
 
4.4 OPTIMISATION OF INTERPRETATION OF RESULTS 
4.4.1 CAPILLARY ELECTROPHORESIS PEAK SIZE 
The primers for this assay have been designed in such a way that the FLT3 primer 
spans approximately 330bp and the NPM1 primer spans approximately 170bp 
(Huang et al., 2008). This then allows for the inclusion of the common internal 
tandem duplication sites and the sites for NPM1 mutations A-F, respectively.  The 
study by Huang et al. (Huang et al., 2008) showed that amplified NPM1-wt product 
was found at approximately 167bp and that the amplified FLT3-wt product was 
found  at approximately 328bp. The NPM1-mut was found to be a single peak at 
approximately 171bp and FLT3-ITD produced large peaks from 349bp upwards 
with the largest ITD peak being 424bp in length. The ITD thus varied significantly 
from the FLT3-wt with a size ranging from 18bp to 94bp. Other studies have 
shown that the FLT3-ITD mutation size varies from 12bp to as many as 204bp 
(Schnittger et al., 2002, Kottaridis et al., 2003). Some reports have even identified 
ITDs as small as 3bp (Schnittger et al., 2002).  
Our results differed from that described above with NPM1-wt approximately 170bp 
in size. The NPM1-mut, did however, remain 4bp larger at 174bp. The results for 
FLT3-wt were also shifted, at approximately 330bp with the mutant peaks ranging 
in size from 15bp- 163bp larger than the wild type.   The peaks appeared to be 
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shifted, with an approximate 2bp difference, from that published by another 
laboratory (Huang et al., 2008) using the same primers. This is not an unexpected 
finding as capillary electrophoresis fragment analysis does not measure an 
absolute size but it is rather an assessment of relative size.  Various factors may 
affect the end result, which include a different instrument, a different polymer, the 
use of a different capillary and the use of a different size standard (Wätzig et al., 
1998). Numerous sample types were assessed including stored BMA samples, 
stored blood slides and fresh blood samples (control samples). All of these yielded 
peaks with a bp size as described above. A single sample that was found to be 
mutation positive for both NPM1 and FLT3-ITD, together with a negative control 
(FLT3-wt/NPM1-wt) was used throughout the rest of the study to confirm 
consistency. 
Up to 23% of patients will have more than one FLT3-ITD mutation present at one 
time. This can include up to five additional bands (Kottaridis et al., 2001, Noguera 
et al., 2002, Kottaridis et al., 2003) and may reflect an underlying genetic 
instability. Additional FLT3-ITD mutation bands were also found in 44% (15/34) of 
the samples assessed in this study. The significance of more than one peak has 
not been confirmed to affect prognosis or treatment response and to date the 
significance of this is unknown (Gale et al., 2008). 
The NPM1-wt fragment lengths range from 169 to 171bp with some samples 
yielding two wild type peaks, a ‘double peak’, which is approximately 1 bp apart 
with or without the presence of a mutant peak. Length polymorphisms in the poly-T 
track in the intronic portion of the amplified fragment have recently been described 
(Szankasi et al., 2008), thus providing an explanation for this finding. Based on 
this the NPM1-wt fragments will occur within this 3bp range and by further 
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extrapolation the NPM1-mut fragments will also range by the same 3bp with an 
expected bp length, from 173 to 175bp. Furthermore, it was found in the literature 
that by using a high fidelity polymerase this wild type ‘double peak’ could almost 
be eliminated and that its presence did not interfere with the identification of any of 
the mutant peaks (Schlenk et al., 2008). These wild type ‘double peaks’, were also 
consistently found in this study, but did not affect the ability to detect mutant peaks 
and for this reason such a high fidelity polymerase was not incorporated into the 
methods of this study. 
 
4.4.2 CAPILLARY ELECTROPHORESIS PEAK INTENSITY 
The assessment of fragment analysis results revealed that the peak intensities of 
both the NPM1 and the FLT3-ITD mutations had a very wide range. Some 
samples had intensities of less than 100 while others were more than 10 000.  
Correspondence with two individuals specialising in the field of myeloid 
leukaemias was initiated (Adam Bagg, personal communication on April 30; 2010 
and Phillippe Szankasi personal communication on May 3; 2010). Both of these 
correspondents had recently published information with regards to the testing 
strategies available for these gene mutations (Szankasi et al., 2008, Wertheim and 
Bagg, 2008, Buban et al., 2011). The presence of low mutant peaks in their 
fragment analysis results was confirmed. Both of these correspondents make use 
of similar methods, both to each other and to the methods described in this study’s 
materials and methods section. The first correspondent (Adam Bagg) reports any 
mutation peak as positive, including those with peak intensities below 100. The 
sensitivity of the assay in use by his laboratory has been confirmed and they are 
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confident that these findings are significant. The second correspondent (Phillippe 
Szankasi) considers mutant peak intensities greater than 100 to be positive.  
The incorporation of an indeterminate group as part of the interpretation of the 
results is worth considering, although this was not performed in the final analysis 
of the results of this study. This will allow for the sample in question to be re-
extracted for PCR, for the original PCR product to be prepared again and 
electrophoresis on the gene  analyser  to take place to assess for fragment 
analysis or alternatively to receive a fresh sample from the patient.  These 
samples will either be bone marrow or peripheral blood depending on the clinical 
scenario e.g. blast count in the blood, or whether treatment has been started.  
As previously mentioned, it is known that FLT3-ITD positivity in an AML patient is 
a poor prognostic feature. The impact of FLT3-ITD positivity, mutant level, size 
and number of mutations in these patients remains uncertain. Recently, it was 
found that the most significant marker for poorer prognosis was mutant level rather 
than the presence of the mutant itself (Gale et al., 2008).  
 
4.4.3 FLT3 RATIO RESULTS 
The reporting of the mutant levels, as recorded on the electropherogram has 
become routine practice. It was recently noted that those with a low mutant to wild 
type level had a better long term outcome while those with a high FLT3-ITD 
mutant ratio were at a higher risk of early relapse (Gale et al., 2008). A previous 
study had suggested that patients with very low FLT3-ITD mutant level ratios had 
a similar prognosis to those who were wild type (Cloos et al., 2006). All of this is 
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available for reporting when making use of the capillary electrophoresis method 
and the allelic burden has been assessed in more detail in the results section. If 
this approach is adopted then the presence of a low mutant peak and the decision 
to call it positive or alternatively indeterminate should have no real impact on 
patient prognosis or on physician treatment decisions compared to those who are 
diagnosed as wild type. This does not, however, mean that these peaks and 
mutant ratios should not be reported. It will remain important for follow up of these 
patients with a definite need to be particularly vigilant.  
The importance of allelic burden is a finding which is also relevant in the 
assessment of other mutation states. JAK2 V617F mutation allelic burden is an 
important prognostic marker in MPN (Theocharides et al., 2008, Hussein et al., 
2009).   
 FLT3-ITD mutant level, however, is affected by a number of factors which include 
the number of blasts present in the sample as well as the number of cells that 
have the mutant clone present (sub-clone).  As mentioned, the study by Gale et al. 
allowed for the division of their patient cohort into three risk group categories. RR 
and OS were affected by the FLT3-ITD allelic burden and was the basis for this 
risk classification (Gale et al., 2008). Of the cases that were FLT3-ITD positive in 
our study and had a mutation level recorded, 50% (15/30) were found to be in the 
low risk category with a mutant to wild type peak of less than 25%.   
Other methods of assessing FLT3-ITD and NPM1 mutants are valuable in order to 
confirm the molecular findings described. 
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4.5 SEQUENCE ANALYSIS 
The “direct visualisation” of this method would have been particularly useful for 
confirmation of the molecular findings. However, none of the samples that were 
sequenced (n=5) revealed the expected mutation. Although DNA sequencing is 
generally a robust technique, problems do occur. This method has limited 
sensitivity due to the background noise in the generated chromatograms and a 
positive result is often dependent on a high mutant/wild type ratio, i.e. requiring at 
least 20% mutant in the sample (Izmailov et al., 2002, Steensma, 2006). This is 
particularly relevant in NPM1 cases in which homozygosity of the mutant has 
never been recorded and in FLT3-ITD where often it is a secondary mutation 
which may only form part of a small clone (Izmailov et al., 2002, Steensma, 2006, 
Falini et al., 2007). Furthermore, the same primers that were used for the PCR 
reaction were also used for the sequencing reaction. This could have resulted in 
the area of interest being too close to the primer and therefore falling into the initial 
area of noise. Some of the traces had short read lengths: a delayed start to the 
trace signal may have resulted in the area of mutation being missed and primer 
dimers may have formed in the sequencing reaction. Methods to improve the 
sensitivity of sequencing include cloning the mutant DNA prior to sequencing or 
blast cell enrichment of the specimen (Hyodo et al., 2003, Kiyoi and Naoe, 2006). 
These methods will be employed as part of the ongoing research. 
 
4.6 CYTOPLASMIC NPM1 ASSESSMENT 
In general aberrant expression of cytoplasmic nucleophosmin can be used as a 
surrogate for NPM1-mut positivity (Falini et al., 2006, Swerdlow et al., 2008). This 
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method of detection of NPM1 mutations was included in the study not only as a 
potential means to confirm the molecular findings but also to assess its potential 
usefulness as an adjunct to capillary electrophoresis.  
A number of limitations are present with this form of detection. This includes that, 
immuno-staining with anti-NPM1 is not used as a single marker but rather anti-C23 
(nucleolin) is used in conjunction with this stain. C23 is used as control as it is 
always nuclear in NPM1 mutation positive cases (Falini et al., 2005). Furthermore, 
this form of NPM1 detection has been optimised for histology only, accurate 
detection of cytoplasmic positivity can be difficult in high nuclear to cytoplasmic 
ratio blasts and its use in detection of MRD is not reported and is unlikely to be 
useful (Falini et al., 2005, Wertheim and Bagg, 2008). Also, the detection of NPM1 
mutations without knowledge of the FLT3 status is unhelpful in the further 
management stratification of these patients. These limitations were also evident in 
the use of this stain in this study cohort.  
The corresponding trephine samples of the bone marrow aspirate slides were not 
always available and as a result only 32 samples were assessed for NPM1 
cytoplasmic positivity (NPM1-mut status). A 73% concordance was found between 
the immuno-histochemical staining and the molecular results.  Although this was 
useful in confirming some of the findings from the molecular assessment, some of 
the samples were found to have equivocal staining and it did not prove to be of 
any value in those cases which have a low NPM1 mutant peak intensity.  
Another alternative would be to use flow cytometric analysis to detect for the 
presence of cytoplasmic nucleophosmin and thereby the presence of the NPM1 
gene mutation (Oelschlaegel et al., 2010). This method may be incorporated into 
further research in this area. 
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4.7 PATIENT CHARACTERISTICS 
An overall assessment of the frequency and general patient characteristics of de 
novo AML in our population had not been recently reported. For this reason all de 
novo AML cases were assessed generally and then for the more specific 
subgroups of NPM1 and FLT3-ITD mutation positivity.   
4.7.1 DEMOGRAPHICS 
There is often a delay in accessing health care in developing countries and this 
results in up to 95% of cancer patients in general being diagnosed late with a 
consequent poor outcome (Andela, 2006) . During this delay nearly half of these 
patients would have sought advice from a traditional healer or private medical 
practioner (Mesfin et al., 2009). The reasons stated for this delay in seeking care 
include hoping for spontaneous remission, a way to defer cost, negative 
perception of health institutions, illiteracy and to avoid the possible diagnosis of 
HIV/AIDS (Yomi and Gonsu, 1995, Mavhu et al., 2010). These are important 
points to consider when assessing patient demographics and comparing results 
from a developing country to that of the developed world. 
Taking this into account, it is known that NPM1 mutations are generally associated 
with de novo AML with no prior history of MDS, MPN or other prior malignancies 
for which treatment was received. The male to female ratio in all subtypes of AML 
is 3:2 but NPM1 mutation positive subgroups have a male to female ratio of 1:1.5 
(Thiede et al., 2006). An unexpected slight female predominance was found in the 
total study cohort of 164 AML cases. In the NPM1 mutation positive cases there 
was a male to female ratio of 1:1.5 which was not statistically significant (P>0.05). 
The reason for the slight female predominance in the AML group as a whole is not 
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certain and would be beyond the scope of this project. However, a recent report 
has indicated that there is often a delay by men in seeking medical assistance with 
regard to certain chronic illnesses (Mavhu et al., 2010). It is possible that this may 
also occur in acute onset illnesses. 
The median age of diagnosis of AML was found to be 40 years in this study cohort  
which is significantly lower than the reported figure of 63 years (Jemal et al., 2005) 
as reported in the cancer statistics of the United States of America. Sub-Saharan 
Africa is known to have vastly different population demographics compared to first 
world western countries, with a much younger population in general: This could 
contribute to the younger age at presentation seen in our study There is also a 
much lower life expectancy mostly due to the HIV pandemic and other infectious 
diseases (Kahn et al., 2007).  
NPM1mutation positivity is commonly found in adults (30%) diagnosed with AML 
with a median age at diagnosis for those who are NPM1-mut only is approximately 
60 years (Thiede et al., 2006). Our data set showed that NPM1-mut only (NPM1-
mut/FLT3-wt) cases were found to be younger than expected with a median age of 
30 years as represented in Figure 3.17. It was, however, noted that patients’ ≥60 
years formed 32% (13/41) of the NPM1-mut positive subgroup while in the NPM1-
wt subgroup those ≥60 years only accounted for 18% (22 /120). An increase in the 
number of older patients with both mutations occurring simultaneously was noted, 
with those ≥60 years accounting for 53% (8/15). There was a statistically 
significant difference noted when assessing those aged ≥60 years in the NPM1-
mut/FLT3-ITD group compared to the NPM1-wt/FLT3-wt group (P<0.002).  This 
seems to indicate a gain in mutations with increasing age.  
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There has been no significant association between FLT3-ITD positivity and age or 
gender in the literature (Kottaridis et al., 2001, Thiede et al., 2002) . No significant 
association was found in this study cohort either. 
4.7.2 FBC AND BLAST COUNT FINDINGS 
AML with mutated NPM1 is a de-novo AML which has been associated with 
certain characteristic findings. These patients are often anaemic and have a 
thrombocytopenia, but present with a higher WCC, platelet count and blast count 
at diagnosis when compared to other AML types (Döhner et al., 2005). The 
anaemia and thrombocytopenia at diagnosis was confirmed in the NPM1-mut 
positive cases as represented in Figure 3.4. 
Those with NPM1-mut only (NPM1-mut/FLT3-wt) were found to have a 
significantly reduced median platelet count when compared to those with FLT3-
ITD only (NPM1-wt/FLT3-ITD) and this appears to be a novel finding as this has, 
to my knowledge, not been documented in any of the international literature.  
In addition, a leucocytosis and high blast cell count was present in the NPM1-mut 
as well as the NPM1-mut only group (NPM1-mut/FLT3-wt), but was not statistically 
different than in the other AML sub-groups assessed in this project. The 
international literature found similar findings as that described above.  
The expected leucocytosis and high blast count in those with FLT3-ITD positivity 
was also found to be present (Suzuki et al., 2007).  The WCC count of those 
cases that were FLT3-ITD positive only (NPM1-wt/FLT3-ITD) was significantly 
increased when compared to those with an NPM1-mut only (NPM1-mut/FLT3-wt) 
(P<0.03), and those without either of the mutations (NPM1-wt/FLT3-wt) (P<0.01). 
This finding has not been documented in the international literature. As a further 
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novel finding, those cases with both mutations in combination (NPM1-mut/FLT3-
ITD) had a significantly (P< 0.04) higher median Hb (9.5 g/dl) when compared to 
the other three groups (NPM1-mut only, FLT3-ITD only and wild type for both gene 
mutations). As the group numbers analysed are small, all of these novel findings 
need to be assessed in greater detail and would form part of future work.  
4.7.3 FAB CLASSIFICATION 
NPM1 mutations occur most commonly in those patients diagnosed as FAB M4 
and M5 and there have been reports that 80-90% of monocytic leukaemias are 
NPM1-mut positive (Falini et al., 2005, Swerdlow et al., 2008). In this study cohort, 
FAB M5 was also found to be the most common subgroup, comprising 40% (8 of 
20) of those who were NPM1-mut positive only (NPM1-mut/FLT3-wt). FAB M2 was 
found to be the second most common group in those who are NPM1-mut positive.                         
Several studies have reported an association of the FLT3-ITD mutation with FAB 
M3 and FAB M5 (in particular M5b). Conversely, it is not commonly associated 
with M6 and M7 (Schnittger et al., 2002, Thiede et al., 2002). A total of 31% (5 of 
16) of the FLT3-ITD positive only samples were classified as FAB M5 according to 
the FAB classification system.   
FAB M5 was found to be the most common classification group, in both the NPM1-
mut only (NPM1-mut/FLT3-wt) and the FLT3-ITD only (NPM1-wt/FLT3-ITD) group. 
In the group negative for both (NPM1-wt/FLT3-wt) these gene mutations FAB M2 
and M3 were the most common FAB classification.  Although, not statistically 
significant these findings concur with that found in the literature(Falini et al., 2005, 
Swerdlow et al., 2008). 
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4.8 IMMUNOPHENOTYPIC ANALYSIS 
Blasts in the NPM1 wt group were found to be significantly more commonly CD34 
positive ((P< 0.05) than in the NPM1 mut group. It was, however, expected that 
most of the NPM1-mut positive samples would be  CD34 negative (Falini et al., 
2005), but only   51% (20 of 39) of NPM1-mut positive samples were CD34 
negative . The reporting of CD34 positivity may be affected by various factors and 
needs to be assessed in more detail. Most studies assess the presence or 
absence of CD34 expression  by means of immuno-histochemistry staining, this is 
not as sensitive as flow cytometric assessment (Falini et al., 2005). Also, of those 
studies that do assess CD34 presence by means of flow cytometric analysis, anti-
CD34 FITC is used. In our centre it is possible that for some of these cases the 
panel of HLA-DR/CD33/CD34 is used in making the diagnosis of AML. This means 
that a PERCP anti-CD34 monoclonal antibody is used, which will be brighter than 
that seen when using  FITC anti-CD34. This may result in the higher estimation of  
CD34 positive cells. Furthermore, Paint-A-Gate PRO Software (BD Biosciences 
Inc., San Jose, CA) is used for flow cytometric analysis, this may also result in an 
over estimation of the positivity of CD34.  
 
4.9 CYTOGENETIC ASSESSMENT 
Of the 164 cases in this study cohort, 21% (34/164) were found to be FLT3-ITD 
positive and 26% (42/164) were NPM1-mut positive while 9% (15/164) were found 
to have dual positivity (NPM1-mut/FLT3-ITD). All of these findings together with 
the propensity for FLT3-ITD to target those with an NPM1-mut are in keeping with 
findings in the literature (Thiede et al., 2006, Swerdlow et al., 2008). 
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Recently research has focused only on those patients who were diagnosed with 
CN AML (Fröhling et al., 2002, Döhner et al., 2005, Falini et al., 2005). Many of the 
adult AML patients in our records did not have their karyotype assessed at 
diagnosis. Some of the pre-analytical reasons included that the test had not been 
requested by the treating doctor, samples had not been sent in the correct tubes 
and in some cases inadequate samples were received. Analytical reasons 
included the relatively common growth failure of the cell culture. As a result, a 
reliable assessment of those who were indeed normal karyotype was not possible 
and the decision to only look at those patients with a confirmed normal karyotype 
was not a feasible option.  
The presence of an aberrant karyotype, including recurrent translocations, 
occurring in conjunction with NPM1 and FLT3-ITD mutations has been reported 
(Suzuki et al., 2005, Verhaak et al., 2005, Thiede et al., 2006, Palmisano et al., 
2007)). As little or no data is currently available in South Africa the decision not to 
limit our assessment to those with either no karyotype or normal karyotype results 
only was made.  Both known associations and any unexpected, novel findings 
could be missed if the sample group was too limited.  
In most laboratories, approximately 25% of AML patients are currently excluded 
from NPM1 and FLT3-ITD  testing due to the failure of cytogenetic analysis and 
are also possibly excluded from the assignment of the prognostically favourable 
genotype (NPM1-mut/FLT3-wt) if a chromosomal aberration is present (Mrózek et 
al., 2007). In view of the above assessment and our findings in this study it may 
indeed be valuable to test all AML patients for both FLT3-ITD and NPM1 
mutations. 
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Palmisano et al found that, from 11 patients who were confirmed NPM1-mut 
positive on sequencing, two were positive for t(15;17) and two were positive for 
inv(16) (Palmisano et al., 2007). Another two patients were found to have complex 
karyotypes.  There has also been a  case report documented, where a patient was 
diagnosed as having an NPM1 mutation (low mutation peak intensity) and was 
found to have not only one recurrent translocation but two (Falini et al., 2008). This 
patient had both a t(8;21) and an inv(16) mutation. When assessing the mutation 
status of our patient cohort with a recurrent chromosomal translocation and an 
NPM1mutation present, a common feature was the presence of a low 
NPM1mutation peak intensity and by association a low NPM1-mut /NPM1-wt ratio. 
The recurrent translocations, as mentioned in the 2008 WHO classification, were 
present only in NPM1 mutation positive samples with mutant peak intensities of 
less than 550. Two other samples (R51 and R35) with a mutation peak intensity 
>550 also had another cytogenetic abnormality noted. Further details are reported 
in Appendix 5.2.  
In view of the limited numbers of patients with dual recurrent translocations and 
NPM1 mutations some of these results reported in the literature have been 
reassessed on a retrospective basis by Falini et al (Falini et al., 2008). Some of 
these samples were found to be negative for NPM1mutation on repeat testing, 
while in others cases, sample registration errors were found for the PCR and/ or 
the karyotyping results (Falini et al., 2008). Other samples, however, could not be 
disregarded as having an error and were found to be correct results. It will, 
certainly be valuable to reassess those patients in our cohort who were found to 
have both recurrent translocations and an NPM1 mutation. Fresh samples at 
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relapse for both FISH and capillary electrophoresis analysis would be particularly 
useful.  
The possibility of using the peak intensity value of >550 for NPM1 mutation 
positivity may also be a realistic consideration as all the recurrent translocations 
which occurred simultaneously with an NPM1 mutation were found in cases with 
NPM1 mutation peak intensities of <550. Reporting of the NPM1-mut/NPM1-wt 
ratio is another assessment tool which is likely to be valuable in the future and is 
readily available from data produced in the capillary electrophoresis assessment. 
This ratio would then be able to correct for the low mutant peak intensities.  
Laboratory error as well as the sensitivities and specificities of the diagnostic test 
may not be the only factors contributing to these findings. Ethnic differences have 
been confirmed to affect disease pathogenesis.  Even in a recent study assessing 
NPM1 mutations in Asian populations, it was found that the incidence of this 
mutation was significantly lower than in European populations (Koh et al., 2009).  
The possibility remains that the occurrence of two or more specific genetic 
markers (in particular NPM1 mutations in conjunction with another) may in fact be 
co-incidental or alternatively a true association, which is as yet not understood. 
The assessment of these recurrent translocations together with NPM1 mutations 
should form part of an ongoing investigation in all future patients diagnosed with 
de novo AML.  
Of the 34 patient samples found to be FLT3-ITD positive, 44% (15/34) of them 
were also NPM1 mutation positive. This was found to be a statistically significant 
association (P<0.05) and is a common finding in most other studies (Thiede et al., 
2006). This is suggestive of the NPM1 mutation being the first of the 2 mutations 
to occur. FLT3-ITD is not as stable and often develops later in the disease process 
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as a secondary event (Cloos et al., 2006, Palmisano et al., 2007, Schnittger et al., 
2009).  
FLT3-ITD is found in all forms of AML, but is commonly associated with CN AML 
and with t(6;9) and t(15;17) (Kottaridis et al., 2003, Slovak et al., 2006). Of the 34 
patients who were found to have a FLT3-ITD mutation, 58% (11/34) had 
cytogenetic abnormalities detected (those with confirmed abnormal FISH analysis 
results were included in this group even though not all of them had a karyotype 
result available), while 42% (8/34) were found to be cytogenetically normal. Of 
those who were FLT3-ITD positive only (NPM1-wt/FLT3-ITD) 13 had a karyotype 
result available of which 38% (5/13) had a normal karyotype (P>0.05). Only 3 of 
the 34 samples that were FLT-ITD positive were also t(15;17) positive (P>0.05).  In 
this study the expected significant association between FLT3-ITD positivity and 
t(15;17)  and CN AML was not found. The total number of those with a cytogenetic 
or FISH result was small and this may have limited accurate assessment.   
 
4.10 ASSESSMENT OF MINIMAL RESIDUAL DISEASE (MRD) 
NPM1 mutations are the most common genetic aberration in CN AML and are one 
of the more stable mutations over the course of the disease (Falini et al., 2009). In 
assessing for MRD, it has also been shown that mutant copy numbers coincide 
well with response to chemotherapy and are predictive of haematologic relapse 
(Gorello et al., 2006). For these reasons there is merit in attempting to use this 
mutation as a potential marker for MRD follow up. Various techniques are 
available for assessing for the presence of NPM1 mutations.  Immuno-
histochemistry and capillary electrophoresis have a diagnostic sensitivity of 
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approximately 100%, with the ability to detect almost all of the NPM1 mutation 
types (A-F). Capillary electrophoresis has an analytical sensitivity of approximately 
5% and thus limits its potential as a test for assessing MRD (Szankasi et al., 2008, 
Wertheim and Bagg, 2008). QPCR has an analytic sensitivity of 0.01-0.1% but is 
limited, in most assays, to only diagnosing NPM1 mutation A (Ottone et al., 2008, 
Wertheim and Bagg, 2008). For most of the other mutations there may be a need 
to develop patient specific primers, which has cost implications. The answer to 
assessing for MRD in our laboratory, as a future undertaking, may lie in using a 
combination of these methods. 
Although using NPM1 as a marker for MRD appears promising, there have been 
two recent reports confirming the loss of this mutation at relapse (Suzuki et al., 
2005, Papadaki et al., 2009) with Papadaki et al. finding this in 9.5% and Suzuki et 
al. finding this in 11.7% of their patient cohorts. They suggest that this may in fact 
be a limitation to its use as a marker for assessing MRD. This particular finding, of 
a loss of NPM1 mutation at relapse, was also noted in a single patient that formed 
part of the longitudinal follow up and was reported as Case 3 in the results section. 
With the reported lower limit analytical sensitivity of approximately 5% and the 
reported evidence of a distinct correlation of NPM1 mutation ratio with blast 
percentage (Papadaki et al., 2009); the relapse blast percentage of 80% in this 
particular case, Case 3, was adequate for NPM1 mutation assessment by means 
of capillary electrophoresis. 
The presence of FLT3-ITD is not considered useful for assessing MRD. At relapse 
some patients have shown a loss, a gain, a change in the length as well as a 
change in the number of FLT3-ITD mutations. A gain can occur in up to 23% of 
patients and may suggest the presence of an oligo-clone which dominates in 
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relapse (Cloos et al., 2006). Patients may gain a new mutation and lose the old 
mutation during disease progression. It is, however, important to continue to 
monitor for this mutation as it has been found that if the FLT3-ITD remained 
present at relapse there had then been a significantly shorter time to relapse and if 
the FLT3-ITD had been lost at relapse the time to relapse was found to be 
significantly longer (Kelly and Gilliland, 2002).  
 
4.11 IMPACT ON CINICAL OUTCOME 
It is has been well established in the recent literature that the presence of an 
NPM1 mutation improves overall survival and confers a better prognosis for CN 
AML patients, while the presence of FLT3-ITD positivity results in much poorer 
prognosis and the combination of the two mutations appears to provide an 
intermediate prognosis (Döhner et al., 2005, Gale et al., 2008). Those patients 
with an NPM1 mutation usually respond well to induction chemotherapy (Arber, 
2001). This sensitivity to chemotherapy may be secondary to the mutated NPM1 
binding to nuclear factor kappa beta (NF-κB) which confers resistance to 
chemotherapy by sequestering it in the cytoplasm and therefore inactivating it 
(Cilloni et al., 2008). When NPM1 is mutated, a NES motif is created which then 
reinforces the Crm-1 (exportin1) dependent movement of NPM1 into the 
cytoplasm (Bolli et al., 2007). Targeting abnormal Nucleophosmin trafficking to the 
cytoplasm by means of Crm-1 inhibitors is a potential target (Dong et al., 2009).  
NPM1 mutations are always heterozygous in AML and it has been suggested that 
some normal NPM1 is required for leukaemic cell survival (Falini et al., 2007). 
 110 
 
Another possibility for therapy might then be to target the residual NPM1-wt which 
the leukaemic cell still requires to survive. (Falini et al., 2009)  
It was also recently found that the addition of an already well known drug, ATRA to 
a conventional chemotherapy regimen improved survival in those patients who 
had an NPM1 mutation only (NPM1-mut/FLT3-wt) (Schlenk et al., 2009).  
FLT3-ITD positivity is well known to have an adverse effect on patient outcome 
and is relatively common in AML patients; this makes it an attractive target for the 
design of specific inhibitory therapies such as FLT3-inhbitors, a specific form of 
TKIs (Sanz et al., 2009). However, the effectiveness of FLT3-inhibitors as single 
agents has been disappointing overall and clinical testing in combination with 
standard chemotherapeutic regimens have shown better results (Levis et al., 
2004). Some of these FLT3 inhibitors, as part of combination chemotherapy, are 
currently in phase III clinical trials (Sanz et al., 2009). 
 
4.12 RECOMMENDATIONS 
Further improvements on testing methodology can be made via a prospective 
study making use of fresh DNA samples. Cases included at diagnosis need to be 
assessed on a longitudinal basis and monitored for survival, time to relapse and 
mutation status at relapse in collaboration with the treating haematologists or 
oncologists.  
Those patients who have been found to be NPM1 mutation positive in conjunction 
with a recurrent translocation should be assessed in more detail. It may be of 
value to obtain a fresh sample from these particular cases if relapse occurs for 
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reassessment of mutation status. This will enable the further elucidation of the 
uncommon finding of an NPM1 mutation and a recurrent cytogenetic translocation 
and allow confirmation of differences in our setting. All patients diagnosed with 
AML should be assessed for NPM1 and FLT3-ITD gene mutations, not only those 
who are assessed to be CN. This decision may need to be reviewed at a later 
stage once sufficient data for our patient population has been obtained and the 
cost implications of testing have been fully evaluated. 
Immunophenotypic interpretation of prospective studies should be assessed in 
more detail. Anti-CD34 FITC only, should be used to determine CD34 positivity on 
these samples and a comparison made to the immuno-histochemical anti-CD34 
stain. It is also suggested that a single person review these results, at least 
initially, in order to exclude inter-observer variation.  
This testing should be expanded to include paediatric patients as well. Despite the 
lower frequency of these mutations in paediatric patients with AML,  approximately 
7.5% will have an NPM1 mutation (Brown et al., 2007) and 5-16.5% (Krstovski et 
al., 2009) a FLT3-ITD mutation. The outcome and treatment strategies for 
paediatric patients are also affected by the presence of these mutations (Zwaan et 
al., 2003, Cazzaniga et al., 2005, Brown et al., 2007).  
Sequence analysis of both mutations but in particular, for NPM1 mutations will be 
useful. This will determine if the commonly reported mutations are indeed also the 
most common in our population and whether it will be financially viable to 
implement the use of Q-PCR in combination with capillary electrophoresis in order 
to better assess for MRD. The primers used for sequencing needs to be re-
evaluated along with the various other possible reasons for the initial failure of this 
technique.  
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Use of a known mutation positive cell line to include as part of the routine assay 
would confirm the reproducibility of our results. 
Consideration could be given to the establishment of a laboratory external quality 
assurance (EQA) programme.  
Other well known gene mutations and various combinations of these such as 
CEBPA, WT1, NRAS, KRAS and MLL-PTD (Kelly and Gilliland, 2002, Mrózek and 
Bloomfield, 2006) should ideally also be assessed as they are also known to affect 
the outcome of patients. As a further project, multiplex mutational testing making 
use of Luminex based systems may be a consideration. Currently, a commercial 
Luminex assay which detects four (A, B, D and J) of the NPM1 gene mutations 
(RNA based) is being validated. This will allow detection of 85-95% of the known 
NPM1 exon 12 mutations (Hafez et al., 2010). The potential exists to assess for 
both the common recurrent translocations (normally determined by karyotyping or 
FISH analysis) as well as these gene mutations and others in one assay 
(Wertheim and Bagg, 2008).This would mean that all the clinically relevant 
mutations for AML could be detected in a single assay. In order for this to be 
feasible all of the PCR and hybridisation conditions for the karyotypic 
abnormalities and gene mutations would need to be similar. 
 
4.13 CONCLUSION 
The presence of both NPM1 and FLT3-ITD mutations were assessed by means of 
a PCR based method. Analysis by Genescanning capillary electrophoresis yielded 
results in which the intensity and exact position of the mutation as well as the 
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mutant level were easily determined.  The PCR method for the detection of these 
gene mutations is relatively simple and visualization is clear.  
The combined assessment of NPM1 and FLT3-ITD allows for identification of 
subgroups of patients with markedly different prognosis.  NPM1-mut only (NPM1-
mut/FLT3-wt) confers a favourable outcome, while FLT3-ITD positivity is generally 
unfavourable, with FLT3-ITD overriding the good prognosis of NPM1 mutation 
positivity when they occur in conjunction.  FLT3-ITD peak intensity relative to the 
FLT3-wt peak intensity is also known to affect prognosis with a high FLT3-
ITD/FLT3-wt ratio predicting a poorer OS and RR (Gale et al., 2008).  
It is well known that the diagnosis, assessment of severity and prognostication of 
most diseases requires not only multiple special investigations but a detailed 
history and clinical examination as well. This is especially true for a complicated 
multi-dimensional disease such as acute leukaemia. The complexity of this 
particular neoplasm is easily evidenced in the WHO classification where numerous 
factors are incorporated into diagnostic algorithms to make the final diagnosis. 
This includes morphology, cyto-chemical stains, immunophenotyping, clinical 
findings and most recently genetic information.  Some of these parameters are 
used to make a diagnosis, whereas others are more specifically used for 
prognostication. When assessing so many parameters at so many different levels 
it becomes evident that not all individuals will always comply with a definitive 
category but indeed groups of patients may differ from the norm. In particular this 
needs to be taken into account when assessing minority groups which are often 
not included in the studies used to establish these international guidelines.  
Currently there is limited data available describing AML in South Africa. This study 
not only provides information about these newly described gene mutations but 
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also gives insight into the epidemiology and patient characteristics of those adults 
diagnosed with de novo AML. The frequency of these mutations in newly 
diagnosed AML patients concurs with reported studies.    
An assessment of these mutations relative to some of the special investigations 
commonly used in our setting was made. This included comparison to routine 
investigations (FBC) and those more specific to the diagnosis of acute leukaemia 
(immunophenotyping and cytogenetics). Some of the findings presented appear to 
be novel. In particular, the occasional occurrence of a recurrent translocation 
together with an NPM1 mutation is an unexpected yet interesting result. 
The determination of the presence of these gene mutations will now form part of 
the standard testing in any patient diagnosed with de novo AML at any of the 
Gauteng provincial hospitals. As part of an ongoing assessment and follow up the 
results obtained from this routine implementation of testing will continue to be 
compared to those parameters described in this study. Furthermore, patient 
outcome will be prospectively assessed in collaboration with the treating 
haematologist. 
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5 APPENDIX 
5.1  FLT3 MUTATION LEVEL 
The AUC of both the mutant and wild type FLT3 peak generated on capillary 
electrophoresis is automatically recorded as part of the electropherogram data and 
is displayed in Figure 5.1. The relative mutant level or allelic burden can then be 
calculated using the following: AUC FLT3-ITD x100/ AUC FLT3-wt +AUC FLT3-
ITD (Gale et al., 2008).  
 
 
Figure 5.1 Electropherogram and data table (GeneMapper software). 
This demonstrates the wt and the mutant peak sizes, intensities and area under the curve for 
Sample R38. 
 
 
5.2  NPM1 AND FLT3-ITD MUTATION POSITIVE SAMPLES 
Table 5.1 includes all the samples which were found to be NPM1 mutation 
positive. Included in this table are the wild type and the mutant size and peak 
intensities. 
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Table 5.1 NPM1-mut positive samples. 
All the wild type and mutation peak intensities and sizes are included. 
 
 SAMPLE NPM1-wt           
SIZE 
NPM1-wt 
INTENSITY 
NPM1-mut 
SIZE 
NPM1-mut 
INTENSITY 
R 18 170.02 8603 173.64 1562 
R 38 170.68 9139 174.69 9160 
R 51 170.34 8585 174.27 7223 
R 52 170.04 8836 174.09 8857 
R 57 170.65 8433 174.14 7000 
R 63 170.14 9040 174.2 9099 
B3 170.38 8809 174.82 9198 
F19 169.28 8692 173.45 8392 
N12 170.7 7616 173.59        
174.44 
8595                   
8573 
N17 169.12 
170.73 
7517                      
7506 
174.7 7785 
N44 169.19 7442 173.24        
174.82 
7330                         
7078 
N99 170.68 9092 174.41 8578 
T1_T28 169.33                   
170.85 
8018                         
7516 
173.35 669 
R 35 170.49 9397 174.61 6077 
N10 170.76 
169.03 
7344                          
7214 
173.44 1415 
N14 169.23 8443 173.95 8686 
N40 169.07 7886 173.92 1684 
N49 169.16                  
170.74 
8765                         
8465 
173.58            
174.42 
523                              
400 
N55 169.32 8507 174.32 8556 
N59 169.96 8907 173.8 8860 
N61 169.29                
170.77 
7724                         
7607 
174.77 8343 
N64 170.25 2320 174.25 611 
N71_N28 170.62 8812 174.51 8542 
T9_R9 170.69 8990 174.9 8862 
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R 11 169.98 9126 174.22 109 
R 17 170.54 1046 174.54 407 
R 21 169.3 8475 173.64 208 
R 31 169.3 8325 173.33 75 
R 3 170.03 9249 173.56 165 
R 8 169.98 8938 173.76 314 
R 10 170.9 9228 173.78 471 
R 53 170.72 8883 173.7 290 
B5 169.43           
171.02 
8495                
8181 
173.88 176 
N24 170.07 8541 173.67 209 
N56 170.71 8870 173.35 386 
R14_F18 169.30 
170.80 
8005                       
8101 
173.61 61 
R30_T7 170.8 9059 173.48 243 
R36_F23 170.76 9233 173.32 161 
T14_F11 170.46 451 174.44 198 
T17 169.33 
170.96 
8661                      
8574 
173.24 189 
R73 169.96 8628 174.63 8736 
T8 169.26 
170.88 
6913                      
6848 
173.47 3793 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type. 
 
Sample R51 had a mutation peak intensity of 7223 and was found to have a 
del(13q) while sample R35 had a peak mutation intensity  of 6077 and was found 
to have an inv(9) on cytogenetic analysis.  The electropherogram plot of Sample 
R51 is displayed in Figure 5.2. 
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Figure 5.2 High NPM1-mut peak intensity in sample positive for del(13q). 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; NPM1-wt, nucleophosmin 1 gene wild 
type. 
 
Table 5.2 and 5.3 includes all the samples which were found to be FLT3-ITD 
positive (NPM1-wt/FLT3-ITD) and positive for both mutations simultaneously 
(NPM1-mut/FLT3-ITD). Included in these tables are the wild type and the mutant 
size and peak intensities. 
 
 
 
 
 
 
NPM1-WT 
170.3-8585 
NPM1-MUT 
174.3-7223 
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Table 5.2 FLT3-ITD positive samples. 
All the wild type and mutation peak intensities and sizes are included. 
 
 SAMPLE FLT3-wt  
SIZE  
FLT3-wt 
INTENSITY 
FLT3-ITD      
SIZE 
FLT-ITD         
INTENSITY 
1.  R 38 330.98 4868 351.52 
375.81                   
376.70 
1465                          
8575                         
9711 
2.  R 51 330.75 9435 378.98                  
408.85 
400                            
8302 
3.  R 57 330.93 9324 345.74               
355.34 
184                               
163 
4.  R 63 330.75 8470 382.23 7644 
5.  B3 330.67 9851 368.48 1439 
6.  F19 329.43 8794 346.52 
356.53 
370.68 
2077                                   
2916              
9430 
7.  N12 330.94 8933 388.02 
396.55 
2383                           
1790 
8.  N17 331.08 9947 348.61 972 
9.  N44 331.04 7809 379.8                 
406.00 
1432                                    
5681 
10.  N99 329.87 
330.92 
4421                  
8143 
351.44                  
359.93 
362.85 
421.51 
679                             
1699                              
196                               
572 
11.  T1_T28 330.81 9680 418.69 3030 
12.  R 11 330.81 9238 360.07 2539 
13.  R 17 331.0 6348 374.1 1565 
14.  R 21 330.88 8485 359.54 1347 
15.  R 27 330.44 8730 371.13 8955 
16.  R 64 330.87 8770 365.51 2418 
17.  R 65 330.55 9755 365.19              
378.15                    
393.5 
1111                                      
1340                           
8139 
18.  F24 330.69 9783 392.32 
415.72                  
424.43 
8149                                  
296                             
8149 
19.  F3 330.81 10032 344.04 
352.34 
2187                             
327 
20.  F4 330.89 8148 391.02 184 
21.  F6 330.07 9034 355.41 81 
22.  N11 330.59 10049 361.59 
374.98 
1005                           
1227                         
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387.76 10350 
23.  N30 330.63 9929 356.77 
376.8 
1776                             
741 
24.  N32 331.19 10234 493.29 881 
25.  N33 331.17 9774 493.33 70 
26.  N37 331.29 9509 355.39 174 
27.  N60 330.68 9044 359.63 9204 
28.  N62 330.89 9379 340.67 
348.5 
365.04 
9483                           
2497                           
9483 
29.  N75 329.78 8694 367.23 499 
30.  N94 330.86 9646 339.28 56 
31.  T15_N31_T27 330.0 9488 385 8309 
32.  T2 330.79 10026 371.22 8688 
33.  T20 330.72 10012 353.98 
382.77 
2637                           
3144 
 
Abbreviations: FLT3-ITD, FMS-like tyrosine kinase receptor gene internal tandem duplication; 
FLT3-wt, FMS-like tyrosine kinase receptor gene wild type. 
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Table 5.3 Samples with dual positivity for NPM1-mut and FLT3-ITD. 
Mutation size and intensity for both are demonstrated. 
 
SAMPLE NPM1-mut   
SIZE 
NPM1-mut 
INTENSITY 
FLT3-ITD SIZE FLT-ITD                      
INTENSITY 
R 38 174.69 9160 351.52 
376.70 
1465                                           
9711 
R 51 174.27 7223 378.98 
408.85 
400                                            
8302 
R 57 174.14 7000 345.74 
355.34 
184                                                  
163 
R 63 174.2 9099 382.23 7644 
B3 174.82 9198 368.48 1439 
F19 173.45 8392 346.52 
356.53 
370.68 
2077                                           
2916                                                     
9430 
N12 173.59                
174.44 
8595             
8573 
388.02 
396.55 
2383                                              
1790 
N17 174.7 7785 348.61 972 
N44 173.24                 
174.82 
7330                    
7078 
379.8 
406.00 
1432                                               
5681 
N99 174.41 8578 351.44 
359.93              
362.85  
421.51 
679                                            
1699                                             
196                                              
572 
T1_T28 173.35 669 418.69 3030 
R 11 174.22 109 360.07 2539 
R 17 174.54 407 374.1 1565 
R 21 173.64 208 359.54 1347 
 
Abbreviations: NPM1-mut, nucleophosmin 1 gene mutant; FLT3-ITD, FMS-like tyrosine kinase 
receptor gene internal tandem duplication. 
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